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1. INTRODUCTION 
1.1 Cancer: 
 Cancer has existed for all of human history. The earliest written record regarding 
cancer is from circa 1600 BC in the Egyptian Edwin Smith Papyrus and describes 
cancer of the breast. 
 Medically it is known as a malignant neoplasm. 
 Cancer is a broad group of diseases involving unregulated cell growth in which 
cells divide and grow uncontrollably, forming malignant tumors, and invading 
nearby parts of the body[1].  
 The cancer may also spread to more distant parts of the body through the 
lymphatic system or bloodstream. 
 Not all tumors are cancerous. Benign tumors do not invade neighboring tissues 
and do not spread throughout the body[2]. 
 There are over 200 different known cancers that affect humans. 
Six characteristics of malignancies have been proposed[3]:  
 Sustaining proliferative signaling,  
 Evading growth suppressors,  
 Resisting cell death,  
 Enabling replicative immortality,  
 Inducing angiogenesis and  
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 Activating invasion and metastasis.  
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps[4]. 
1.2 Types: 
 Carcinoma: 
 A carcinoma is tumor tissue derived from putative epithelial cells whose genome has 
become altered or damaged to such an extent that the cells become transformed and begin to 
exhibit  abnormal malignant properties[5] [6]. 
Ex. Lung cancer, Prostate cancer, Breast cancer, Colon cancer, Pancreatic cancer. 
 Sarcoma: 
 A sarcoma  is a cancer that arises from transformed cells of mesenchymal origin[7]. 
Ex.  Cancers of bone, cartilage, fat and nerve.  
 Lymphoma: 
 Lymphoma is a cancer develop in the lymph nodes, spleen and bone marrow[8]. 
 Leukemia: 
Leukemia is a cancer of the blood or bone marrow[9]. 
 Germ cell tumor: 
 Germ cell tumor is a cancer derived from Germ cells(testicle and overy) [10]. 
 
 Blastoma: 
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A blastoma is a type of cancer, more common in children that is caused by malignancies 
in precursor cells[11]. 
1.3 Causes of cancer: 
 Cancers are primarily an environmental disease with 90–95% of cases attributed to 
environmental factors and 5–10% due to genetics[12]. 
 Chemical: 
Ex. Alcohol and tobacco smoking. 
Tobacco smoking is associated with many forms of cancer[13] and causes 90% of lung 
cancer[14]. 
 Diet and Exercise: 
Diet, Physical activity and obesity are related to approximately 30–35% of cancer 
deaths[15]. 
Ex. Betel nut chewing with oral cancer, high salt diet linked to gastric cancer. 
 Infection: 
Worldwide approximately 18% of cancer deaths are related to infectious diseases. 
This proportion varies in different regions of the world from a high of 25% in Africa to 
less than 10% in the developed world. Viruses are the usual infectious agents that cause 
cancer but bacteria and parasites may also have an effect. 
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  A virus that can cause cancer is called an oncovirus. 
 These include human papillomavirus (cervical carcinoma),Epstein–Barr virus (B-
cell lymphoproliferative disease and nasopharyngeal carcinoma), Kaposi's sarcoma 
herpesvirus (Kaposi's sarcoma and primary effusion lymphomas), hepatitis B and 
hepatitis C viruses (hepatocellular carcinoma) and Human T-cell leukemia virus-1 (T-cell 
leukemias). Bacterial infection may also increase the risk of cancer, as seen in 
Helicobacter pylori-induced gastric carcinoma. Parasitic infections strongly associated 
with cancer  include Schistosoma haematobium (squamous cell carcinoma of the bladder) 
and the liver flukes, Opisthorchis viverrini and Clonorchis sinensis (cholangiocarcinoma) 
[16]
 . 
 Radiation: 
 Ionizing radiation: Medical imaging and Radon gas 
 Non-ionizing radiation: Ultraviolet radiation and mobile phone radiation. 
 Radiation can cause cancer in most parts of the body, in all animals and at any 
age, although radiation-induced solid tumors usually take 10–15 years and can take up to 
40 years, to become clinically manifest and radiation-induced leukemias typically require 
2–10 years to appear[17] . 
 Heridity: 
 Less than 0.3% of the population are carriers of a genetic mutation which has a 
large effect on cancer risk and these cause less than 3–10% of all cancer[18] . 
Hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) which is 
present in about 3% of people with colorectal cancer[19] . 
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 Physical agents: 
A prominent example of this is prolonged exposure to asbestos, naturally occurring 
mineral fibers which are a major cause of mesothelioma, which is a cancer of the serous 
membrane, usually the serous membrane surrounding the lungs. Other substances in this 
category, including both naturally occurring and synthetic asbestos-like fibers such as 
wollastonite, attapulgite, glass wool and rock wool, are believed to have similar effects[20]  
 Hormones: 
Some hormones play a role in the development of cancer by promoting cell 
proliferation[21] . 
Hormones are important agents in cancer of the breast, endometrium, prostate, ovary, 
testis, thyroid cancer and bone cancer[22]. 
Insulin-like growth factors and their binding proteins play a key role in cancer cell 
proliferation, differentiation and apoptosis, suggesting possible involvement in 
carcinogenesis[21]. 
1.4 Pathophysiology: 
 Cancer is fundamentally a disease of tissue growth regulation failure. In order for a 
normal cell to convert into a cancer cell, the genes which regulate cell growth and differentiation 
must be altered[23]. 
 The affected genes are divided into two broad categories.  
1. Ongogenes- Promote cell growth and reproduction 
2. Tumor suppressor genes-Inhibit cell division and survival[24]. 
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Both oncogenes and tumour suppressor genes exert their effect on tumour growth through 
their ability to control cell division (cell birth) or cell death (apoptosis). Normal function of 
tumour suppressor gene is usually to restrain cell growth and this function is lost in cancer[25]. 
Genetic alteration: 
 Genetic changes can occur at different levels and by different mechanisms. The gain or 
loss of an entire chromosome can occur through errors in mitosis. More common are mutations, 
which are changes in the nucleotide sequence of genomic DNA. 
 Large-scale mutations involve the deletion or gain of a portion of a chromosome. 
 Small-scale mutations include point mutations, deletions and insertions, which may occur 
in the promoter region of a gene and affect its expression, or may occur in the gene's coding 
sequence and alter the function or stability of its protein product. 
Epigenetic alteration: 
Epigenetic alterations refer to functionally relevant modifications to the genome that do 
not involve a change in the nucleotide sequence[26]. 
Examples of such modifications are changes in DNA methylation (hypermethylation and 
hypomethylation) and histone modification and changes in chromosomal architecture (caused by 
inappropriate expression of proteins such as HMGA2 or HMGA1) [27]. 
P53: 
The tumour suppressor, p53, is encoded in human by the TP53 gene. The gene itself is 
located on the short arm of chromosome 17 (locus: 17p13.1) and spans 20kb[28]. 
It plays a significant role in regulation of cell cycle and helps in preventing cancer. 
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Structurally, p53 is a 393 amino acid long polypeptide with seven domains including an 
acidic N-terminus transactivation domain, a zinc DNA-binding core domain, and a 
homooligomerisation domain[29]. p53 also contains a proline-rich and a second transactivation 
domain which are involved in the pro-apoptotic activity of p53 and its interaction with other 
proteins[30]. The homo-oligomerisation domain is essential for tetramisation of p53 and 
subsequent in vivo activity[31]. p53 is involved in many cellular functions including apoptosis, 
cell cycle arrest, DNA repair and senescence. It is modulation of these functions that have led to 
p53 being labelled ʻthe ʻguardian of the genomeʼ. Furthermore, mutations to TP53 which result 
in functionally deficient p53 expression, are present in over 50% of all tumours[32]. Under normal 
conditions, p53 is maintained at a low level by ubiquitination, which targets the protein for 
degradation by the proteasome[33]. This is achieved via interaction with the negative regulator of 
p53, MDM2, an E3 ubiquitin ligase which binds p53 protein and marks it for degradation[34]. 
MDM2 forms a stable complex with p53 by binding to the N-terminal domain[35].  The C-
terminal RING domain of MDM2 is vital to its ability to mark p53 for degradation, as it recruits 
ubiquitin-conjugating enzyme E3, resulting in polyubiquitination of p53[36]. 
 The p53 transcriptional programme can be activated by a variety of cellular stressors such 
as DNA damage, oxidative stress, osmotic shock and nucleotide depletion[37] [38] [39] [40]. The first 
step in p53 activation involves destabilisation of the MDM2-p53 repressor complex, which 
increases p53 half-life and induces a rapid accumulation of  p53 protein. Secondly, p53 is 
subjected to post-translational modifications such as acetylation and phosphorylation, which 
activate its transcriptional activity by driving nuclear accumulation of p53[41]. Activation of p53 
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plays a major role in coordinating cell cycle arrest, DNA repair and apoptosis in response to 
DNA damage[42]. 
Apoptosis induced by p53 involves the role of many mediators, important one being bax 
protein. Bax protein is a member of Bcl-2 protein family. p53 binding site located in the 
regulatory region of the gene which directly activates transcription of Bax gene and when over 
expressed Bax induces apoptosis.   
Two major events occurring on activation of p53 are  
-Half life of p53 is increased, leading to its accumulation in damaged cells  
-Serves as a transcription regulator in stressed cells.  
In normal humans p53 is continually produced and degraded in cells, which is associated 
with MDM2 binding, induced by p53 by negative feedback loop. But mutant p53 do not induce 
MDM2 and starts accumulating at high concentration. Mutant p53 can also inhibit normal p53 
protein levels[43]. 
Bcl2: 
 Bcl-2 derives its name from B-cell lymphoma 2. Bcl2 is a family of regulatory protein 
that regulates the cell death (apoptosis), by either inducing (pro-apoptotic) it or inhibiting it (anti-
apoptotic) [44] [45]. Apoptosis is the process of programmed cell death, when altered gives rise to a 
number of human diseases like cancer, autoimmune disorders and some viral infections.  
Anti-apoptotic proteins of this family includes Bcl-2, Bcl-xL, Mcl-1, Bcl-w and A-1 
which suppresses the cell death[46] [47]. 
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 Pro-apoptotic proteins of this family includes Bax, Bak, Bik, Bad and Bid which causes 
promotion of cell death[48] [49]. 
 High expression of anti-apoptotic members like Bcl-2 and Bcl-xL which are found in 
human cancers leads to neoplastic cell expansion by interfering with normal cell death 
mechanism. 
 Bcl-2 protein is coded by Bcl-2 gene. Bcl-2 gene plays a role in number of cancers like 
lung, breast, prostate and melanoma[50]. 
 It has been proposed that Bcl-2 functions via intracellularly generated reactive oxygen 
species (ROS) [51] [52] [53]. Bcl-2, however, prevents apoptosis induced under very low oxygen 
conditions, suggesting that the mechanism of Bcl-2 action may not necessarily involve the 
regulation of ROS activity[54]. Therefore, despite progress in defining some of the physiological 
roles of Bcl-2, the biochemical mechanism of its action remains unknown. 
 Bax gene was the first pro-apoptotic member of the Bcl-2 family, which promotes 
apoptosis by competing with Bcl-2. Tumour suppressor protein p53 up regulates the expression 
of Bax and Bax is proven to be involved in apoptosis mediated by p53. 
 Majority of Bax is found in cytosol and upon initiation of apoptosis; it undergoes a 
conformation shift and fits into outer mitochondrial membrane. Further it results in the release of 
cytochrome c and other pro-apoptotic factors from mitochondria leading to apoptosis[55]. 
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Tumor necrosis factor : 
Tumor necrosis factor (TNF, cachexin, or cachectin, and formerly known as tumor 
necrosis factor alpha or TNFα) is an adipokine involved in systemic inflammation and is a 
member of a group of cytokines that stimulate the acute phase reaction. 
It is produced chiefly by activated macrophages. 
It can also produced by other cells such as CD4+ lymphocytes, NK cells and neurons[56]. 
The primary role of TNF is in the regulation of immune cells. 
TNF, being an endogenous pyrogen, is able to induce fever, apoptotic cell death, 
cachexia, inflammation and to inhibit tumorigenesis. 
Dysregulation of TNF production has been implicated in a variety of human diseases 
including alzheimer's disease[57], cancer[58], major depression[59] and inflammatory bowel disease 
(IBD) [60]. 
TNF can bind two receptors, TNFR1 (TNF receptor type 1) and TNFR2 (TNF receptor 
type 2). TNFR1 is expressed in most tissues, where as TNFR2 is found only in cells of the 
immune system[61]. 
When ligand binds to the TNF receptors, adaptor protein TRADD binds to death domain 
which enables subsequent protein binding, thereby initiating three pathways, namely NF-κβ 
pathway, MAPK pathway and by induction of death signaling[62].  
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Figure.1.1 Signaling pathway of TNFR1. Dashed grey lines represent multiple steps. 
 
Interleukin: 
Interleukins are a group of cytokines  that were first seen to be expressed by white blood 
cells (leukocytes). The function of the immune system depends in a large part on interleukins. 
The majority of interleukins are  synthesized by helper CD4 T lymphocytes, as well as through 
monocytes, macrophages and endothelial cells[63]. Interleukin 6 (IL-6) is a pro inflammatory 
cytokine producing multifunctional effects[64].  
Interleukin-6 interact with interleukin-6 receptor[65] [66] and glycoprotein-130[67]. 
De regulation in IL-6 production and signaling are associated with chronic inflammatory 
diseases, auto immune disorders and cancer. 
Inhibition of IL-6 production, its receptors or the signaling pathways are current trends of 
novel therapies for a wide range of diseases. High serum IL-6 levels were detected in patients 
with lung, breast, prostate, colorectal, gastric, pancreatic, ovarian and renal cell cancers. High 
serum IL-6 levels were associated with progressive diseases and poor survival[68]. 
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IL-6 stimulates the inflammatory and auto-immune processes in many diseases such as 
diabetes[69], atherosclerosis[70], major depressive disorder[71], alzheimer's Disease[72], systemic 
lupus erythematosus[73], multiple myeloma[74], cancer[75], Behçet's disease[76], and rheumatoid 
arthritis[77]. 
Advanced/metastatic cancer patients have higher levels of IL-6 in their blood[78]. 
Hence there is an interest in developing anti-IL-6 agents as therapy against many of these 
diseases[79] [80]. 
1.5 LUNG CANCER: 
 Lungs are located in the chest, when we breathe air goes through our nose, down the 
windpipe and into the lungs, where it spreads through tubes called bronchi. Most lung cancer 
begins in the cells that line these tubes. Lung cancer is a disease characterized by uncontrolled 
cell growth in tissues of the lung. If left untreated, this growth can spread beyond the lung in a 
process called metastasis into nearby tissue or other parts of the body[86]. 
 Cancers that start in the lungs are known as primary lung cancers are carcinomas that are 
derived from epithelial cells[86]. 
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 The main types of lung cancer are:  
 Small cell lung carcinoma (SCLC) also known as ‘oat cell carcinoma’  
 Non small cell lung carcinoma (NSCLC).  
 
Small cell lung cancer is a fast growing type of lung cancer and it spreads more quickly 
than non small cell lung cancer.  
Two different types of SCLC are  
 Small cell carcinoma (oat cell cancer)  
 Combined small cell carcinoma.  
 
Figure 1.2 A chest X-ray showing 
a tumor in the lung (marked by 
arrow) 
Figure 1.3 Cross section of a human 
lung: The white area in the upper 
lobe is cancer; the black areas are 
discoloration due to smoking. 
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Non small cell lung cancer (NSCLC) is the most common type of lung cancer. It usually 
grows and spreads more slowly than small cell lung cancer.  
Three forms of NSCLC are  
 Adenocarcinomas are found in the outer area of the lung.  
 Squamous cell carcinoma are usually found in the centre of the lung next 
to an air tube (bronchus).  
 Large cell carcinomas can occur in any part of lung where they tend to 
grow and spread faster than other two types[87]. 
CANCER- GLOBAL REVIEW: 
 In 2008 approximately 12.7 million cancers were diagnosed (excluding non-melanoma 
skin cancers and other non-invasive cancers) [81]. 
 In 2010 nearly 7.98 million people died with cancer[82]. 
 Cancers account for nearly 13% of all deaths each year with most common being  
 Lung Cancer (1.4 million deaths)  
 Stomach Cancer (7,40,000 deaths)  
 Liver Cancer (7,00,000 deaths)  
 Colorectal Cancer (6,10,000 deaths)  
 Breast Cancer (4,60,000 deaths) [83]. 
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Overall men have 44% risk of developing cancer at some time during their lives and 
women have 38% lifetime risk. In the year 2010 in USA, incidence of lung cancer ranked second 
after prostate cancer in male and breast cancer in female.  
In deaths caused due to cancer, lung cancer outnumbered prostate cancer in male and 
breast cancer in women to top the chart with 86220 deaths in men and 71080 deaths in women[84] 
[85]
. 
 Lung cancer is the most common cancer and the most common cause of cancer 
deaths in world.  
From the above mentioned data it is quite clear that Lung Cancer is the most deadly 
disease of all cancers and let’s shift our focus purely to lung cancer. 
CAUSES: 
Smoking: 
Smoking, particularly of cigarettes, is the main contributor to lung cancer[88]. 
 Cigarette smoke contains over 60 known carcinogens[89] including radioisotopes from 
the radon decay sequence, nitrosamine and benzopyrene. Additionally, nicotine appears to 
depress the immune response to cancerous growths in exposed tissue[90]. 
 Across the developed world, 90% of lung cancer deaths in men during the year 2000 
were attributed to smoking (70% for women). Smoking accounts for 80–90% of lung cancer 
cases[91]. 
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 Passive smoking: the inhalation of smoke from another's smoking is a cause of lung 
cancer in nonsmokers.  Studies from the US, Europe, the UK, and Australia have consistently 
shown a significantly increased risk among those exposed to passive smoke[92]. 
 Passive smoking causes about 3,400 deaths from lung cancer each year in the USA[93]. 
Radon gas: 
 Radon is a colorless and odorless gas generated by the breakdown of radioactive radium, 
which in turn is the decay product of uranium, found in the Earth's crust. The radiation decay 
products ionize genetic material, causing mutations that sometimes turn cancerous. Radon is the 
second-most common cause of lung cancer in the USA[93]. 
 The risk increases 8–16% for every 100 Bq/m³ increase in the radon concentration[94]. 
Asbestos: 
 Asbestos can cause a variety of lung diseases, including lung cancer. Tobacco smoking 
and asbestos have a synergistic effect on the formation of lung cancer[95]. 
 Asbestos can also cause cancer of the pleura, called mesothelioma (which is different 
from lung cancer) [96]. 
Air pollution[97] and heredity[98] are the other factors of lung cancer. 
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Pathogenesis: 
 Lung cancer is initiated by activation of oncogenes or inactivation of tumor 
suppressor genes.[99] Oncogenes are believed to make people more susceptible to cancer. Proto-
oncogenes are believed to turn into oncogenes when exposed to particular 
carcinogens.[100] Mutations in the K-ras proto-oncogene are responsible for 10–30% of lung 
adenocarcinomas.[101] The epidermal growth factor receptor (EGFR) regulates cell 
proliferation, apoptosis, angiogenesis and tumor invasion. [101]] Mutations and amplification of 
EGFR are common in non-small-cell lung cancer and provide the basis for treatment with 
EGFR-inhibitors. Her2/neu is affected less frequently.[ 101] Chromosomal damage can lead to loss 
of heterozygosity. This can cause inactivation of tumor suppressor genes. Damage to 
chromosomes 3p, 5q, 13q, and 17p are particularly common in small-cell lung carcinoma. 
The p53 tumor suppressor gene, located on chromosome 17p, is affected in 60-75% of 
cases. Other genes that are often mutated or amplified are c-MET, NKX2-1, LKB1, PIK3CA, 
and BRAF.[101] 
Symptoms[102]: 
Respiratory symptoms: coughing, coughing up blood, wheezing or shortness of breath 
Systemic symptoms: weight loss, fever, clubbing of the fingernails, or fatigue 
Symptoms due to local compress: chest pain, bone pain, superior vena cava 
obstruction, difficulty swallowing 
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If the cancer grows in the airway, it may obstruct airflow, causing breathing difficulties. 
The obstruction can lead to accumulation of secretions behind the blockage, and 
predispose to pneumonia.  
 Depending on the type of tumor, so-called paraneoplastic phenomena may initially attract 
attention to the disease. In lung cancer, these phenomena may include Lambert–Eaton 
myasthenic syndrome(muscle weakness due to autoantibodies), hypercalcemia, or syndrome of 
inappropriate antidiuretic hormone (SIADH). Tumors in the top of the lung, known as Pancoast 
tumors, may invade the local part of the sympathetic nervous system, leading to Horner's 
syndrome (dropping of the eyelid and a small pupil on that side), as well as damage to 
the brachial plexus. 
 Many of the symptoms of lung cancer (poor appetite, weight loss, fever, fatigue) are not 
specific. In many people, the cancer has already spread beyond the original site by the time they 
have symptoms and seek medical attention. Common sites of spread include the brain, 
bone, adrenal glands, opposite lung, liver, pericardium, and kidneys.  
About 10% of people with lung cancer do not have symptoms at diagnosis these cancers 
are incidentally found on routine chest radiography[103]. 
Prevention: 
 Prevention is the most cost-effective means of decreasing lung cancer development. 
While in most countries industrial and domestic carcinogens have been identified and banned, 
tobacco smoking is still widespread. Eliminating tobacco smoking is a primary goal in the 
prevention of lung cancer, and smoking cessation is an important preventive tool in this process. 
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 Policy interventions to decrease passive smoking in public areas such as restaurants and 
workplaces have become more common in many countries[104]. 
Treatment: 
 Treatment for lung cancer depends on the cancer’s specific cell type, its spread and 
patient’s performance status. Most common treatments include palliative care, chemotherapy and 
radiation therapy. 
 For non small cell lung cancers, the treatment depends on the stage of cancer. 
Surgery is the most common treatment for patients with non small cell lung cancer. 
Surgery includes 
 One of the lobes of the lung (lobectomy)  
 Only small part of the lung (wedge or segment removal)  
 Entire lung (pneumonectomy)  
Chemotherapy: 
 In SCLC cisplatin and etoposide are commonly used. 
 NSCLC is cisplatin or carboplatin and other drugs are gemcitabine, paclitaxel, 
docetaxel, etoposide or vinorelbine 
 Adjuvant chemotherapy which refers to use of chemotherapy after apparently 
curative surgery to improve the outcome. 
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  For potentially curable SCLC cases, chest radiotherapy is often recommended in 
addition to chemotherapy. Prophylactic cranial irradiation (PCI) is a type of radiotherapy to the 
brain, used to reduce the risk of metastases. Palliative care or hospice management plays a great 
role in patients with terminal disease. Chemotherapy may be combined with palliative care in 
treatment of the NSCLC[105]. 
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LUNG CANCER IN INDIA[106]: 
INDIA MALE FEMALE BOTH SEXES 
Population (thousands) 610618 570793 1181412 
Number of new cancer cases 
(thousands) 
430.1 518.8 948.9 
Age-standardised rate (W) 92.9 105.5 98.5 
Risk of getting cancer before age 
75 (%) 
10.2 10.8 10.4 
Number of cancer deaths 
(thousand) 
321.4 312.1 633.5 
Age-standardised rate (W) 71.2 65.5 68 
Risk of dying from cancer before 
age 75 (%) 
8 7.1 7.5 
 
   
5 most frequent cancers  Lung   
 
 Breast   
 
Cervix uteri   
 
Oesophagus   
 
Lip, oral cavity   
Table 1.1 shows the burden of lung cancer in India as reported in the Globocan Report 2008. 
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2. SCOPE OF THE WORK 
With cancer being a leading cause of death worldwide, it seems obvious that it would be 
an important research focus for any medical research institute[107]. 
Lung cancer is one of the most common cancers we have and a large number of people 
die of this disease every year. The disease is often discovered in a late stage, but also in earlier 
stages lung cancer patients have worse outcome than patients with other cancers. Even without 
spreading to other organs during stage I the survival rate of lung cancer is under 70%. In 
comparison, for example breast cancer there is 95% survival in stage I and also Lung cancer is 
the first most common malignancy among population worldwide. With limited success 
pertaining to available treatment options for lung cancer, alternative and complimentary 
strategies need to be developed[108]. 
 Several studies have revealed that Epidermal growth factor receptor; a member of 
receptor tyrosine kinase has been over expressed and identified as a therapeutic target for non 
small cell lung cancer.  
Tyrosine kinase inhibitors like Erlotinib, Gefitinib and monoclonal antibodies have been 
recently approved in treatment of lung cancer, but the response rates to these drugs are modest 
and therefore new strategies to treat human lung carcinomas are still a major focus of research. 
Even though significant progress has been made in cancer prevention and treatment, the 
development of effective treatment regimens remains one of the greatest challenges in the area of 
cancer therapy. Hence there arises a need for continuous search of safer and more effective 
chemoprevention and treatment to improve the efficacy and reduce the cost of cancer care. 
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Cancer chemoprevention with natural phytochemical compound is an emerging strategy to 
prevent, impede, delay or cure cancer[109]. 
India is one of the earliest civiliza-tions that have recognized the importance of herbal 
products for disease management, nutrition and beauty enhancement. With the discovery of 
several new molecules from herbs for treating dreaded diseases like cancer and the relative safety 
of these products, the global demand for medicinal plant products has increased in recent years. 
More than 30% of the pharmaceutical preparations are based on plants (Shinwari and 
Khan, 1998). An increasing reliance on the use of medicinal plants in the industrialized societies 
has been traced to the extraction and development of  several drugs and chemotherapeutics from 
medicinal plants. Searching for new drugs in plants implies the screening the plants for the 
presence of novel  compounds and investigation of their biological activities. 
 Many medicinal plants contain large amount of chemical components having broad 
spectrum of pharmacological activities. Anticancer activities are mainly due to phenolic acids, 
flavanoids and phenolic diterpenes. Natural products have long been a rich source of cure for 
cancer, which has been the major cause of death in the past decades[110] 
 Taxol, one of the most outstanding drug used for the treatment of metastatic ovarian, 
breast carcinoma and small cell lung cancer have been obtained from bark of western 
yew tree.  
 Etoposide, a semisynthetic derivative of podophyllotoxin, a plant glycoside being used in 
treatment of testicular tumors, lung cancer and bladder cancer.  
 Topotecan and irinotecan are two recently introduced semisynthetic analogues of 
camptothecin and anti tumor principle obtained from Chinese tree.  
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 Vincristine, vinblastine, colchicines and ellipticine are other important molecules from 
plant source.  
There are nearly 250000 species of plants out of which more than one thousand plants 
have been found to possess significant anticancer properties[111]. 
Considering the toxicities which arise from cytotoxic drugs like bone marrow 
depression, alopecia, lymphocytopenia and occurrence of secondary cancers like leukemia 
and lymphomas, the search further intensifies for the toxicity free herbal remedy for cancer, 
which acts by without interfering with the body’s natural healing process[112]. 
 
Evolvulus alsinoides L. (Convolvulaceae), commonly known as ‘shankhpuspi’ in India, 
Africa and the Philippines, is an important medicinal plant employed for different ailments in 
India traditionally. 
The herb was used to treat dysentery. Mohammedan physicians used the plant as a 
general tonic to strengthen the brain and memory and to treat fever. Evolvulus alsinoides was 
used to treat bowel problems and to promote conception. The entire plant was considered 
astringent and useful for treating  haemorrhages and there are a variety of other medical 
applications, including use as an adaptogenic, antiphlogistic, antipyretic, antiseptic, aphrodisiac, 
febrifuge, stomachic, tonic and vermifuge, in the treatment of asthma, bronchitis, scrofula, 
syphilis, or in “controlling night emissions” and to promote wound healing. 
Its medicinal properties like anti-inflammatory, antipyretic, antidiarrhoeal, 
antidiabetic, antioxidant, antifungal, antimicrobial, antidyskinesia and anthelmintic 
properties were scientifically evaluated and reported. 
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Potential effect of  Evolvulus alsinoides on hair growth also reported. 
But there was no report for the evaluation of its anticancer activity focusing on gene 
expression levels and protein levels in cancerous cells along with apoptosis study.  
So the study was carried out to evaluate the anticancer effect of various extracts of leaves 
of Evolvulus alsinoides in human lung cancerous cell line A549 using various in vitro models. 
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3. OBJECTIVE 
 
 
 
 To identify the Phytochemical constituents present in Ethyl acetate, Ethanol and Petroleum 
ether extract of Evolvulus alsinoides. 
 
 To evaluate the cytotoxic activity of Ethyl acetate, Ethanol and Petroleum ether extract of 
Evolvulus alsinoides  in human lung cancerous cell line A549 and to establish IC5O 
concentration.  
 
 To evaluate the Apoptotic effect of effective extract of Evolvulus alsinoides . 
 
 To evaluate the Protein levels in the effective extract of Evolvulus alsinoides  treated 
cancerous cell line.  
 
 To evaluate the Gene expression levels in the effective extract of Evolvulus alsinoides  
treated cancerous cell line.  
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4. PLANT PROFILE 
 
Figure 4.1. Evolvulus alsinoides Linn 
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Plant name :  Evolvulus alsinoides[113]  
Kingdom Plantae 
Sub-kingdom Tracheobionta 
Super-division Spermatophyta 
Division Magnoliophyta 
Class Magnoliopsida 
Sub-class Asteridae 
Order Solanales 
Family Convolvulaceae 
Genus Evolvulus 
Species Alsinoides 
 
Vernacular names:  
Tamil  :  Vishnukranti, 
Malayalam :  krishnakranti, 
Telugu :  Vishnukranta,  
Kannada :  Shankhapushpi.  
Hindi  :  Shankhauli,  
Sanskrit :  Vishnu krantha, Harikrantha, Shankha pushpi,  
English :  Dwarf morning glory,  
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Distribution: 
Widely distributed in tropical and subtropical regions throughout the world.  It grows 
commonly as a weed in open and grassy places throughout India, ascending at 6000ft.  
Parts used: whole plant 
Description: [114] 
Leaves: Leaves are small, entire, elliptic to oblong, obtuse, apiculate, base acute and 
densely hairy. Petiole is minute or nearly absent. Bracts are linear and persistent.  
Flowers: Flowers mostly solitary in upper axils. Corolla blue rotate and broad funnel 
shaped, Calyx  is lobed, lanceolate and the tip acute. Peduncle is long and axillary.  
Branches: Its branches are annual, numerous, more than 30 cm long, often prostrate, 
slender and wiry with long hairs.  
Chemical constituents:  
The plant contains an alkaloid-shankhapushpine. Fresh plant contains volatile oil and 
potassium chloride. It also contains a yellow neutral fat, an organic acid and saline substances. 
Three alkaloids- evolvine, betaine, and an unidentified compound have been isolated.  
Uses: [115] 
 Nootropic agent,  
 Chronic bronchitis.  
 Used in fever, nervous debility, loss of memory, also in syphilis and scrofula.  
 It is used as Rasayan. Whole plant is used as hepatoprotective  
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Traditional medicinal uses: [116] 
 The whole herb is used medicinally in the form of decoction with cumin and milk 
in fever, nervous debility, loss of memory and syphilis.  
 Decoction of the drug, with Ocimum sanctum is administered in fevers 
accompanied by indigestion or diarrhea. Decoction was given in cases of malarial 
fever.  
 The root is used by the santals, for intermittent childhood fever,  
 The leaves are made into cigarettes and smoked in chronic bronchitis and asthma.  
 The oil promotes the growth of hair. 
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5. REVIEW OF LITERATURE 
5.1 WORK DONE IN Evolvulus alsinoides: 
Adaptogenic, anxiolytic and anti-amnesic activity: 
Alok Nahata et al.,2009 Ethanol extract of the aerial parts of the drug was evaluated for 
CNS activity by using elevated plus maze test, open field exploratory behavior and rota rod 
performance experiments. The ethanol extract as well as its ethyl acetate and aqueous fractions 
was tested in experimental models employing rats and mice. The extracts were also studied for 
their in vitro antioxidant potential to correlate their anxiolytic activity[117].  
Kiran Babu Siripurapu et al.,2005 The improvement in the peripheral stress markers 
and scopolamine-induced dementia by Evolvulus alsinoides in the chronic unpredictable stress 
and acute stress models indicated the adpatogenic and anti-amnesic properties of Evolvulus 
alsinoides, against a well known adaptogen i.e. Panax quinquefolium[118].  
GuptaP et al.,2007 Phenolics and flavonoids, isolated form bioactivity-guided 
purification of n-BuOH soluble fraction from the ethanol extract of Evolvulus alsinoides, were 
screened for antistress activity in acute stress models. Stress exposure resulted in significant 
increase of plasma glucose, adrenal gland weight, plasma creatine kinase and corticosterone 
levels[119].  
Mehta CR et al.,1959 Effects of methanolic extracts of roots of Evolvulus alsinoides 
(MEEA) on acute reserpine-induced orofacial dyskinesia showed increased vacuous chewing 
frequencies (VCMs) and TPs in acute reserpine-treated animals compared with vehicle-treated 
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animals. Chronic treatment significantly reversed the reserpine-induced VCMs and TPs in a 
dose-dependent manner, decreased the locomotor activity as well as the transfer latency in acute 
reserpine-treated rats[120]. 
Antioxidant: 
  Cervenka F et al.,2008 Antioxidant substances were isolated and identified from 
Evolvulus alsinoides by preparing fractions of phenolic and non-phenolic compounds. Results of 
antioxidant activities of Evolvulus alsinoides from 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays 
were not as high as expected. The need of more antioxidant tests with different action 
mechanisms and also in-vivo studies with Evolvulus alsinoides were suggested[121].  
 Ethanolic extracts and water infusion of Evolvulus alsinoides were tested for their 
antioxidant activity in the 2, 2′-azinobis-3-ethyl-benzothiazoline-6-sulfonic acid radical cation 
decolorization assay. Inhibition of lipid peroxidation by plant infusions was carried out using 
spontaneous lipid peroxidation of rat brain homogenate, and IC50 values were determined. The 
results from the ABTS assay showed that the ethanolic extract of Sida cordifolia was found to be 
most potent (IC50 16.07 µg/ml), followed by Evolvulus alsinoides (IC50 33.39 µg/ml) and 
Cynodon dactylon (IC50 78.62 µg/ml).  
Immunomodulatory activity: 
Ganju L  et al.,2003 The crude extracts of Emblica officinalis and Evolvulus alsinoides 
were evaluated for immmunomodulator activity in adjuvant induced arthritic rat model. The anti 
inflammatory response of both the extracts was determined by lymphocyte proliferation activity 
and histopathological severity of synovial hyperplasia. Both the extracts showed a marked 
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reduction in inflammation and edema. At cellular level immunosuppression occurred during the 
early phase of the disease. There was mild synovial hyperplasia and infiltration of few 
mononuclear cells in E.officinalis or Evolvulus alsinoides treated animals. The induction of nitric 
oxide synthase (NOS) was significantly decreased in treated animals as compared to controls[122]. 
Evolvine hydrochloride 
Krishnamurthy TR  et al.,1959 The hydrochloride of alkaloid, evolvine was reported to 
exhibit lobeline-like action on the cardiovascular system. In cats, the drug demonstrated 
sympathomimetic activity. The blood pressure remained elevated for a longer duration as 
compared to adrenaline. Increase in peripheral pressure was observed on local injection of the 
drug[123]. 
Antiulcer and anticatatonic activity 
Purohit MG et al.,1996 The in vivo evaluation of the alcoholic extract of Evolvulus 
alsinoides revealed its marked antiulcer and anticatatonic activity[124]. 
Anti Diarrhoeal activity: 
Dhana Lekshmi U.M et.al 2011 The extract of E. alsinoides showed dosedependent 
effects in controlling the diarrhoea. The results are similar to those of the standard drug 
diphenoxylate with regard to severity of diarrhoea[125]. 
Antiinflammatory effect 
Dhana Lekshmi U.M et.al 2011 Carrageenan-induced rat paw oedema was markedly 
inhibited by oral pre-treatment with the Evolvulus alsinoides extract (250mg/kg and 500mg/kg 
body weight doses) and indomethacin (20mg/kg body weight dose). In the acute inflammation 
model, a dose of 250mg/kg body weight of the extract showed significant inhibition (P < 0.05) at 
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3 and 4h, whereas indomethacin and the extract (500mg/kg body weight) exhibited significant 
inhibition at 2, 3, and 4h[125]. 
Antipyretic studies 
Dhana Lekshmi U.M et.al 2011 The plant extract produced a reduction in hyper pyrexia 
induced by yeast injection in rats, with activity being pronounced within 90min after 
administration of the extract. Also, within 2h of administration of the extract, the plant extract 
was as effective as paracetamol in reducing hyperthermia (P < 0.05) [125]. 
Learning behavior and memory enhancement activity: 
 Nahata et al., 2010 Two doses (100 and 200mg/kg p.o.) of the ethanol extract and ethyl 
acetate and aqueous fractions were administered in separate groups of animals. Both doses of all 
the extracts of EA significantly improved learning and memory in rats[126]. 
Anthelmintic and  Antimicrobial activities: 
 G. K. Dash et al.,2002 The results of antimicrobial activity revealed that the extract 
exhibited activity against  Pseudomonas aeruginosa and Escherichia coli but inactive against 
Staphyloccus aureus and Candida albicans[127]. 
Hair Growth: 
 Bhaiji Amrita et al.,2012 Petrolium ether and methanolic extracts of Evolvulus 
alsinoides has significant hair growth potency in albino rats. The extracts were incorporated into 
oleaginous base and applied topically on shaved denuded skin of albino rats for 30days. Time 
required for hair growth initiation and completion was significantly reduced(P< 0.01) [128]. 
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lipid metabolism: 
 Duraisami gomathi et al.,2013 The ethanolic extract of Evolvulus alsinoides 
supplementation is useful in hyperlipidemia prevention during diabetes mellitus[129]. 
Phytochemical analysis: 
Omogbai B.A et.al.,2011 showed phytochemical analysis of ethanolic and water extract 
of Evolvulus alsinoides indicated the presence of Glycosides, Alkaloids, Saponins, Tannins, 
Flavonoids, Volatile oil in ethanolic extract and indicated the presence of Glycosides,alkaloids in 
water extract[130]. 
Duraisamy Gomathi et.al 2012 showed phytochemical analysis of ethanol, chloroform, 
petroleum ether and ethyl acetate extracts of Evolvulus alsinoides. The study indicates the 
difference in the presence of Glycosides, Alkaloids, Saponins, Tannins, Flavonoids, Volatile oil, 
and Steroids in above extracts[131]. 
Acute toxicity Studies: 
Agarwala N et.al.,1977 showed that the ethanolic (95%) extract of Evolvulus alsinoides 
possess CNS depressant activity with LD50 7500mg/kg[132]. 
5.2 A549: 
A549 cells are adenocarcinomic human alveolar basal epithelial cells which was first 
developed by D.J. Giard et al., by removing and culturing of cancerous lung tissue in the 
explanted tumour of a 58year old Caucasian male. When cultured in vitro they grow as 
monolayer cells, adherent to the culture flask. These cells are squamous in nature and are 
responsible for diffusion substances such as electrolytes and water across the alveoli of lungs. 
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Membrane phospholipids in cells are maintained by lecithin and high levels of desaturated fatty 
acids which are synthesized by these cells. A549 can be anchored or suspended in a solution in 
vitro. 
 A Levy et al.,2011 found that Cassia alata leaf extract exhibits cytotoxic activity in 
A549 lung cancer cells that is dependent on the activation of caspase8. These preliminary results 
could be justified by the cytotoxic activity of the flavonoid kaempferol which is present in C 
alata species. Similar cytotoxic activity induced by kaempferol has been reported in ovarian 
cancer cells. Furthermore, kaemp-ferol has been linked to caspase8 and caspase3 activation. 
Preliminary analysis of the C alata extract using HPLC has identified kaempferol as a major 
constituent in the leaf extract[133]. 
 Qing-Yi Lu et al.,2009 found that the effect of green tea extract on lung cancer (A549) 
cell line they found that Green tea extract stimulates the expression of lamin A/C in a dose- 
dependant fashion and that the proteins were present both in nucleoplasm and cytoplasm. Green 
tea extract induced lamin A/C and annexin I may work together to modulate cell motility[134]. 
 Pourhassan Mohammad et.,al 2011 found the inhibitory effect of Curcuma longa 
extract on telomerase activity in A549 lung cancer cell line[135]. 
5.3  5-Fluorouracil (5FU) : 
 Sreelatha et al.,  2011 reported the Evaluation of anticancer activity of ethanol extract of 
Sesbania grandiflora (Agati Sesban) against Ehrlich ascites carcinoma in Swiss albino mice. 
Sesbania grandiflora extracts showed significant decrease in (p<0.01) tumor volume, viable cell 
count, tumor weight and elevated the life span of EAC bearing mice. Hematological profile such 
as RBC, hemoglobin and lymphocyte count reverted to normal level in EESG treated mice. The 
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extracts significantly (p<0.05) decreased the levels of lipid peroxidation and significantly 
(p<0.05) increased the levels of GSH, SOD and CAT. The results showed that the ethanol extract 
of Sesbania grandiflora was effective in inhibiting the tumor growth in ascitic models and that is 
comparable to 5-Fluorouracil[136]. 
 M. Thirumal et al., 2012 reported invitro  anticancer activity of tecomastans (l.) 
ethanolic leafextract on human breast cancer cell line (mcf-7). Tecomastans is called as yellow 
elder in english. Crude ethanolic extract of Tecomastans leaves were examined for their anti 
cancer activity invitro by testing on MCF-7 breast cancer cell lines using 5-FU as a standard. 
Activity confirmed by MTT assay[137]. 
5.4 P53: 
 Yeung-Leung Cheng et al., 2008 reported The Extract of Hibiscus syriacus inducing 
apoptosis by activating p53 and AIF in Human Lung Cancer Cells. The root bark of Hibiscus 
syriacus has been used as an antipyretic, anthelmintic and antifungal agent in Asia. The 
antiproliferative effects of H. syriacus on human lung cancer cells were evaluated with MTT 
assay. The apoptotic activity was detected by Hoechst 33342 DNA staining and annexin V 
staining. The expression of caspases, p53, apoptosis induced factor (AIF), Bcl-2 and Bax were 
evaluated with Western blotting. The in vivo anticancer activity was evaluated using A549-
xenograft model. The acetone extract of H. syriacus (HS-AE) exhibited a better cytotoxic effect 
on lung cancer cells than its methanol extract (HS-ME) or water extract (HS-WE). The 
IC50 values of HS-AE on A549 (adenocarcinoma), H209 (squamous cell carcinoma) or H661  
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(large cell carcinoma) lung cancer cells ranged from 14 to 22µg/ml after 48hours of 
treatment[138]. 
 Jiayu Gatoso et al.,(2011) reported the apoptotic effect of ethanolic extract of 
Scutellaria baicalensis and its active components in lung cancer cell lines A549, SK-LU-1 and 
SK-MES-1 using 2D gel electrophoresis coupled with protein fingerprinting, flow cytometry and 
immune blotting analysis. It was observed that following treatment with the extract, increased 
expression of key proteins like p53 and bax were directly related to the enhancement of apoptotic 
effect[139]. 
5.5 Bcl2: 
 Azizi E et al.,2009 reported the Evaluation of p53 and Bcl-2 genes and proteins 
expression in human  breast cancer T47D cells treated with extracts of Astrodaucus persicus  
(Boiss.) in comparison to Tamoxifen. since tumorigenesis is thought to result  from a series of 
progressive gene alterations, including activation of oncogenes and inactivation  of tumor 
suppres sor genes, expression of two such genes, p53 and Bcl-2 that are believed to play  a 
crucial role in tumorigenesis and cell death were determined. The results suggest that the 
methanolic extracts of Astrodaucus persicus  especially its root extract may contains bioactive 
compounds, probably coumarins that prevents  proliferation of T47D breast carcinoma cells by 
mechanisms such as apoptosis[140]. 
 Araujo Junior RF et al., 2013 reported Maytenus ilicifolia dry extract protects normal 
cells, induces apoptosis and regulates Bcl-2 in human cancer cells. Maytenus ilicifolia is widely 
used in traditional Brazilian medicine to treat stomach conditions including nausea, gastritis, and  
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ulcers. The apoptotic effects of a spray-dried extract of M. ilicifolia (SDEMI) was evaluated 
using human hepatocellular cells (HepG2), colorectal carcinoma cells (HT-29) and normal 
keratinocytes (HaCaT). Positive caspase-3 staining and down-regulation of Bcl-2 were observed, 
consistent with the induction of cell death detected in these cell lines[141]. 
5.6 TNF: 
 Leong, Perng char et al.,2012 has reported that Apigenin, a natural plant flavones 
induces apoptosis via tumour necrosis factor and Bcl 2 mediated pathways. It has been shown 
that apigenin inhibits the growth of SCC25 and A431 cells and induces cell cycle arrest in the 
G2/M phase. It has been reported that apigenin possess antioxidant property and induces cell 
apoptosis via up regulation of tumour necrosis factor receptor (TNF-R), Bcl 2 mediated caspase 
dependant cell death pathways in SCC25 cells and TNF related apoptosis inducing lligand 
receptor (TRAIL-R) [142]. 
 Hasan TN et al.,2011 reported the Anti-proliferative effects of organic extracts from root 
bark of Juglans Regia L. (RBJR) on MDA-MB-231 human breast cancer cells and role of Bcl-
2/Bax, caspases and Tp53. The study was undertaken to investigate the effect of root bark of 
Juglans regia (RBJR) organic extracts on cell proliferation and to determine the molecular 
mechanism of RBJR-induced cell death by determining the expression of Bcl-2, Bax, caspases, 
Tp53, Mdm-2 and TNF-alpha in MDA-MB-231 human breast cancer cells. Real Time PCR and 
western blot analysis revealed that the expression of of Bax, caspases, tp53 and TNF-alpha was 
markedly increased in MBA-MB-231 cells treated with the RBJR extract[143]. 
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Kim TY et al.,2009 reported the Ethyl alcohol extracts of Hizikia fusiforme sensitize AGS 
human gastric adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-
mediated apoptosis[144].  
5.7 Interleukins: 
 Dipak Giri et.al., 2001 reported that Interleukin-6 is an Autocrine Growth Factor in 
Human Prostate Cancer. They  found that interleukin (IL)-6 protein concentrations are increased 
∼18-fold in clinically localized prostate cancers when compared to normal prostate tissue. The 
concentration of IL-6 receptor is increased eight fold in the prostate cancer tissues and is 
increased in the cancer cells by immunohistochemistry. These findings strongly support the 
hypothesis that IL-6 acts as a significant autocrine growth factor in vivo for primary, androgen-
dependent prostate cancers. It was concluded that IL-6 antagonist may play a role in treatment of 
prostate cancer[145]. 
 Sizhi Paul Gao et al.,(2007) reported that tyrosine-phosphorylated STAT3 (pSTAT3) is 
found in 50% of lung adenocarcinomas and cell lines expressing these persistently activated 
mutant EGFRs also produced high IL-6 levels. IL-6 expression is substantially elevated in and 
IL-6 is secreted by, multiple lung cancer cell lines that harbor EGFR mutations. EGFR is a 
membrane-bound receptor tyrosine kinase and on ligand binding, EGFRs initiate activation of a 
series of cellular signal transduction pathways that regulate cell proliferation and survival. The 
EGFR either is mutated or shows altered expression in a variety of human cancers, including 
carcinomas of the lung, breast, head and neck, ovary and bladder. Blockade of the IL-
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6/gp130/JAK pathway led to a decrease in pSTAT3 levels resulting in decreased 
tumorigenesis[146]. 
5.8 Plasma C Reactive protein: 
According to Oliveira EB et al.,(1979) complete amino acid sequence was derived for 
human c reactive protein and it was found to contain 187 amino acids in a single polypeptide 
chain. Based on its amino acid composition, minimum molecular weight of 20,946 daltons was 
calculated for human CRP and it coincides with the molecular weight of 21500 established by 
gel filteration of CRP in 5.0 M guanidine chloride[147]. 
Chaturvedi et al., reported the risk of C-reactive protein and its association with lung 
cancer. A nested case control study of 592 lung cancer patients and 670 controls were carried out 
and CRP levels were measured. It was reported that increase in CRP levels were associated with 
increased risk of lung cancer. The levels were reported to be high in case of smokers and in lung 
cancer patients when compared to former smokers and 2 to 5 years before diagnosis of cancer 
respectively[148]. 
5.9 Phosphohistidine Phosphatase: 
Xu A et al., (2010) reported that 14 KDa phosphohostidine phosphatase (PHP14) was the 
first protein histidine phosphatase to be discovered. Its role in lung cancer cell migration and 
invasion was reported. It was reported that knockdown of PHP14 expression in highly metastatic 
lung cancer CL 1-5 cells inhibited migration and invasion in vitro without altering cell 
proliferation. Over expression of PHP14 in NCI H1299 cells promoted migration and invasion 
in-vitro. Role of metastatic properties of PHP14 in vivo was evaluated by experimental 
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metastasis assay and it was found that experimental metastasis in vivo was extensively inhibited 
by PHP14 knockdown. The mechanism involved in involvement of PHP14 in cell migration, 
invasion and metastasis was further examined by proteomics analysis. The results of this study 
revealed that PHP14 was probably involved in cyto skeletal reorganization and it was supported 
by actin filament (F actin) staining. It was concluded that PHP14 may be functionally important 
in lung cancer cell migration and invasion of lung cancer cells mediated through modulation of 
actin cytoskeleton rearrangement[149]. 
Su Xia Han et al., (2012) reported that PHP14 is highly expressed in hepatocellular 
carcinoma (HCC) tissues and cell lines when compared with adjacent non cancerous human liver 
tissues and cells. Lenti virus mediated delivery of small interfering RNA (siRNA) was used to 
knockdown the expression of PHP14 in HCC cell line and the effects of PHP14 on cell growth 
was investigated in vitro. It was found that cell proliferation was inhibited and cell apoptosis was 
markedly increased. Flow cytometry analysis was used to examine how PHP14-si affects cell 
cycle and it was found that cells after treatment with PHP14 si for 96hours, there was significant 
increase in G1 phase population in all HCC cells and it indicated that knockdown of PHP14 
expression inhibited cell proliferation, which was necessary for entering into S phase. It was 
concluded that knockdown of PHP14 expression by lenti virus delivered siRNA may be useful in 
treatment of HCC[150]. 
5.10 Soxhlet Extraction: 
Thendral Hepsibha.B et al.,2010 reported In vitro studies on antioxidant and free 
radical scavenging activities of Azima tetracantha. Lam leaf extracts. The air dried and 
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powdered leaves were extracted in soxhlet extractor successively with petroleum ether, hexane, 
ethyl acetate and methanol .The successive extracts were evaporated to dryness and then stored 
residue was used for analysis. Results of this study shows that A. tetracantha leaves are good 
source of natural phenolic compounds. The methanolic extract of the A. tetracantha leaves 
showed better free radical capacity against different reactive oxygen /nitrogen species, among 
other extracts although with different efficiencies[151]. 
S.J.Kulkarni et al., reported Extraction and purification of curcuminoids from Turmeric 
(curcuma longa L.). Fresh rhizomes were Dried at 50˚c in a hot air oven for six hours. Dried 
rhizomes were cut in small pieces, powdered by electronic mill. Six gm of sample were taken 
into a thimble and placed in a Soxhlet apparatus, were set up with various solvent from non polar 
to polar. 250 ml of solvent was added and extracted according to their boiling point for seven 
hours. The solvents used were chloroform (B.P.=61˚c), ethyl acetate (B.P.=77˚c), methanol 
(B.P.=65˚c) and acetone (B.P.=56.53˚c) [152].  
5.11 MTT assay: 
 Nor Azurah Mat Akhir et al., 2011 reported cytotoxicity of aqueous and ethanolic 
extracts of Ficus deltoidea on Human Ovarian Carcinoma Cell Line. MTT assay was used to find 
the cell growth profile and IC50 concentration of the test compound. MTT assay is a rapid and 
high accuracy colorimetric approach that widely used to determine cell growth and cell 
cytotoxicity, particularly in the development of new drug. It measures cell membrane integrity 
by determining mitochondrial activity through enzymatic reaction on the reduction of MTT to 
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formazan. IC50 value was 224.39 and 143.03µg/ml for the aqueous and ethanolic extract, 
respectively[153]. 
 Valko.v et al.,2007 reported anti-proliferative activity of plant extracts from genus 
Philadelphus.L. MTT assay was employed to assess cell viability. The cell proliferation test is 
based on the ability of the mitochondrial succinate tetrazolium reductase system to convert 
yellow tetrazolium salt MTT to purple fromazan dye.  Effects of extracts were expressed by 
IC50[154]. 
5.12 Microscopic Studies: 
 Aied M Alabsi et al.,2013  reported apoptosis induction, cell cycle arrest and invitro 
aanticancer  activity of Gonothalamin in a Cancer Cell Lines. HeLa cells were quantified using 
propidium iodide  (PI) and acridine-orange (AO) double staining according  to standard 
procedures and examine under fluorescence  microscope. After gonothalamin treatment HeLa 
cell death via apoptosis increased significantly (*P < 0.05) in time-dependent manner[155]. 
 Shruti Nair et al.,(2011) reported the anticancer activity of alcoholic and aqueous 
extracts of Moringa oleifera on Hela cells. Anti proliferative effect was assessed by MTT assay 
and apoptosis of cancer cells were confirmed by DNA fragmentation test and ethidium bromide-
acridine orange staining. It was reported that staining the cells which was treated with different 
concentrations of Moringa oleifera aqueous extracts showed viable cells green with intact nuclei 
and non viable cells with bright orange chromatin[156]. 
5.13 DNA Fragmentation: 
Abhimanyu kumar Jha et al.,(2012) reported the apoptotic effect of ethanolic extract of 
Ocimum sanctum, Azadirachta indica and Withania somnifera in SiHa cell line. The IC50 values 
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of the plant extract was established using MTT assay. It was reported that IC50 concentration of 
ethanolic extracts of leaves of Ocimum sanctum and Azadirachta indica and roots of Withania 
somnifera treated in squamous cervical cancer cell line SiHa, resulted in formation of 
internucleosomal fragments of DNA after 48 hours of treatment[157]. 
Arulvasu C et al., 2010 reported induction of apoptosis by the aqueous and ethanolic 
leaf extract of Vitex negundo L. in MCF-7 human breast cancer cells . DNA preparation an 
agarose gel electrophoresis was carried out. Visualization carried  by ethidium bromide staining 
under UV transilluminator.  DNA isolated from cells treated with 200µg/ml and 300µg/ml of 
extract pattern that is characterize the apoptotic cell death after 48hr[158]. 
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6. MATERIALS AND METHODS 
6.1 PLANT COLLECTION: 
 The plant Evolvulus alsinoides Linn was collected from Komaneri, Tuticorin district on 
July 2013 and was identified and authenticated by Professor V. Chelladurai , Research officer- 
Botany (Retd), Central Council for Research in Ayurveda and Siddha , Government of India. 
Instruments used during the course of study: 
1. Soxhlet Apparatus  
2. CO2 Incubator  
3. Cooling Centrifuge  
4. Gel Photo Station  
5. Deep freezer (-20˚C)  
6. Bio Analyzer  
7. Real time RT PCR  
8. Gel Electrophoresis  
9. Inverted Microscope  
10. Analytical balance  
11. Rotary Evaporator 
12. Nano Drop. 
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Study Centre: 
 Life teck Research laboratories vadapalani  in collaboration with Institute of 
Pharmacology, Madras Medical College, Chennai-03. 
Preparation of Extract: 
 The Plant were shade dried at room temperature and was subjected to size reduction to a 
coarse powder by using dry grinder. 50grams of this coarse powder was packed into soxhlet 
apparatus and was subjected to extraction sequentially with 500ml of petroleum ether, ethyl 
acetate and ethanol. The extraction was continued until the colour of the solvent in the siphon 
tube became colourless. Extraction procedure was carried out in Institute of Pharmacology, 
Madras Medical College, Chennai. Extracts of ethyl acetate and ethanol were subjected to 
evaporation by using Rotary evaporator at 60°C.  
 
The percentage of the yield from the plant Evolvulus alsinoides using different solvents is given 
in Table 6.1. 
EXTRACT 
Plant material used for 
Extraction Yield in (gm) Percentage Yield(%) 
Ethanol 50gm 8.6 17.2 
Ethyl acetate 50gm 5.7 11.4 
Petrolium ether 50gm 1.8 3.6 
TOTAL 32.2 
Table 6.1 The percentage of the yield from the plant Evolvulus alsinoides using different 
solvents 
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6.2 PHYTOCHEMICAL STUDIES: 
The freshly prepared extracts of ethyl acetate, ethanol and petroleum ether were subjected to 
phytochemical screening for the presence or absence of active phytochemical constituents by 
following methods[130] [131]. 
Test for alkaloids:  
Crude extract was treated with few drops of dilute hydrochloric acid and filtered. The filterate 
was tested with various alkaloidal reagents such as 
Mayer’s reagent  : Cream precipitate 
Dragendroff’s reagent  : Orange brown precipitate 
Wagner’s reagent  : Reddish brown precipitate 
Test for Steroids:  
Salkowskis test: 
Crude extract was mixed with 2ml of chloroform. Then 2ml of conc. sulphuric acid was 
added carefully and shaken gently. Appearance of reddish brown colour ring indicated the 
presence of steroids. 
Test for Flavanoids:  
Lead acetate test: 
Crude extract was treated with few drops of lead acetate solution. Appearance of yellow 
colour precipitate indicate the presence of flavanoids. 
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Alkaline reagent test: 
Crude extract was treated with few drops of sodium hydroxide solution. Formation of 
intense yellow color, which becomes colorless on addition of dilute acid, indicates the presence 
of flavonoids.  
Shinoda test: 
Crude extract was treated with 5ml 95% ethanol, few drops concentrated hydrochloric 
acid and 5grams magnesium turnings, appearance of pink colour indicated the presence of 
steroids. 
Test for phenols and tannins:  
Crude extract was mixed with 2ml of 2% solution of ferric chloride. Appearance of violet 
colour indicate the presence of phenolic compounds and tannins.  
Crude extract was dissolved in water and treated with 10% of lead acetate solution, 
appearance of white precipitate indicate the presence of tannins and phenolic compounds. 
Test for Proteins:  
Millions test: 
Crude extract was mixed with 2ml of millions reagent. Appearance of white precipitate 
which turns red on gentle heating, indicates the presence of proteins. 
Test for Carbohydrates:  
Fehling’s test: 
Crude extract was treated with equal volume of Fehling A and Fehling B reagents and 
mixed together and gently boiled. Appearance of brick red precipitate at the bottom of the test 
tube indicate the presence of reducing sugars. 
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Test for Glycosides:  
Liebermann’s test: 
Crude extract was mixed with 2ml of chloroform and 2ml of acetic acid. Mixture was 
cooled in ice and conc. sulphuric acid was added. Colour change from violet to blue to green 
indicates the presence of steroidal nucleus. 
Test for Terpenoids:  
5ml of each extract was mixed in 2ml of chloroform. 3ml of concentrated sulphuric acid 
was then added to form a layer. A reddishbrown precipitate colouration at the interface formed 
indicated the presence of terpenoids. 
6.3 IN VITRO ANTI CANCER ACTIVITY: 
 MTT Assay, Fluorescent microscopic studies, DNA fragmentation studies, cell cycle 
analysis, apoptosis, Gene expression studies including protein assay and RT-PCR were carried 
out in LIFETECK Research centre Vadapalani, Chennai. 
Preparation of Minimum Essential Medium : 
Cells when cultured in vitro are in need of nutritional requirements to support their 
growth, maintenance, survival and division. The need for this nutritional requirements for 
survival of the cells in vitro can be fulfilled by provision of Minimum Essential Medium. 
This media is prepared by using HIMEDIA protocol. 
This is the medium used for passaging and growing of A549 cells throughout the study. 
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Preparation: 
Materials Required: 
 Minimum essential medium in powder form(MEM Powder). 
 Penicillin (100IU/ml) 
 Streptomycin(100µg/ml) 
 Amphotericin B 
 Foetal bovine serum (FBS) 10%  
 L-glutamine (3%)  
 Phenol red  
 Sodium bicarbonate (7.5%) 
Procedure: 
Step1: 
 Sterilized Millipore distilled water is taken. 
 Powder form of MEM was dissolved in 1litre of pre sterilized Millipore distilled water, 
mixed well and closed. 
Step2: 
 Then the medium was sterilized. 
 Sterilization Duration  : 15mins 
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 Sterilization temparature : 121°c 
 Sterilization Pressure  : 15lbs 
Step3: 
856ml of sterilized MEM was taken in a 1000ml flask and to it each ml of penicillin, 
streptomycin, phenol red and amphotericin B was added and mixed well.  
Step4: 
10ml of 3% L-glutamine, 100ml of FBS and 30ml of 7.5% sodium bicarbonate was 
added to make up the volume to 1000ml.  
pH was adjusted to 7.2 – 7.4 and the medium was stored for two days at 37°c and the pH 
was checked and transferred to the refrigerator.  
PASSAGING OF CELL LINES: [159] 
Materials Required: 
Cell Line: 
The cell line chosen for this study is human lung cancerous adherent cell line A549, an 
adenocarcinomic human alveolar basal epithelial cells. The cell line was procured from National 
Centre For Cell Science(NCCS), Pune. It was transferred to the laboratory and stored in an 
incubator at 37°c and 5% CO2, to reach 90% of confluency. 
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Procedure: 
 The culture flask containing the adherent cells (primary culture) was removed from the 
incubator.  
 The culture flask was transferred aseptically to the bio safety cabinet along with 
minimum essential medium and TPVG solution after confirming its 90% confluency with 
the help of inverted microscope.  
 The primary culture was passaged /sub cultured to required number of culture flasks for 
further study.  
 The cap of the culture flask was opened and with the help of micropipette the medium 
was aspirated from the culture flask and discarded.  
 200µl of TPVG solution was added to the culture flask and rinsed well to remove any 
adhering medium and later the solution was aspirated and discarded.  
 500-1000µl of TPVG solution was again added to the culture flask and the solution was 
spread evenly to cover the entire surface of the culture flask.  
 The flask was then incubated for 5minutes for detachment of adhered cells from the 
monolayer (cell detachment can be viewed and confirmed under microscope after 5 
minutes of incubation).  
 After detachment of cells from the monolayer, the culture flask was transferred back to 
the bio safety cabinet. The detached cells were suspended completely in the TPVG 
solution by re suspending it with the help of micropipette.  
                                 Materials and Methods 
 
Institute of Pharmacology, MMC Page 54 
 
 The TPVG solution containing the detached cells were aspirated from the culture flask 
and distributed into 7 new tissue culture treated culture flasks for further studies.  
 5ml of fresh minimum essential medium was added to all 7 culture flask containing the 
TPVG solution with suspended cells, such that it covers the entire surface of the flask.  
6.3.1 MTT Assay: [153] [154] 
 It is otherwise called as Tetrazolium Salt Assay/ Microculture tetrazolium test. 
 MTT Assay is an in vitro method for anticancer drug screening, which has been 
internationally accepted. 
 MTT is a yellow water soluble tetrazolium salt. MTT assay utilizes a colour reaction in 
measurement of viability of cells. 
Principle: 
 Chemically MTT is  3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl--tetrazolium bromide 
which contain tetrazolium ring. MTT salt colour is yellow. Living cells contain Mitochondrial 
enzyme succinate dehydrogenase that cleves the tetrazolium ring. This converts the MTT to an 
insoluble purple formazan. Amount of formazan formed is directly proportional to number of 
viable cells. DMSO has been used as a solubilisation solution, which dissolves serum as well as 
the purple formazan product. The absorbance at 570nm was measured with a UV- 
Spectrophotometer to measure the colour intensity. 
Advantages: 
 Used for both adherent and suspension cell lines.  
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 Simple and easy to perform.  
 Hundreds of cell samples can be scanned simultaneously, which enables testing of 
various concentrations of the substance under study.  
 Used to determine IC50 of the test substance.  
Materials Required: 
 96 well microtitre plates  
 Fully grown/confluency reached cells in culture flask  
 Minimum essential medium with 10% FBS  
 TPVG solution  
 Plant extract – Ethyl acetate, Ethanol, Petroleum ether(1000,500,250,125,62.5,31.2,15.6 
and 7.8µg/ml) 
 Drug – 5-Fluorouracil(1000,500,250,125,62.5,31.2,15.6 and 7.8µg/ml) 
 MTT (5mg/ml in PBS - pH 7.4)  
 DMSO solution (0.1% v/v)  
 Aluminium foil  
 Micropipette  
 Phenol red free medium  
 Tryphan blue  
 Bio safety cabinet  
 Tissue culture flask  
 Reagent bottles  
 Inverted microscope  
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 CO2 incubator  
 UV-Chamber 
 Neubar chamber  
Procedure: 
Culture flask containing the adherent cells were taken from the incubator and checked for 
its confluency.  
After confirming the confluency, the adherent monolayer cells were detached to form a 
cell suspension by adding an ml of TPVG solution and incubating it for 5minutes.  
After incubation, the TPVG solution containing cells were taken from the culture flask 
and transferred to the falcon tubes and was subjected to centrifugation at 8000rpm for 5minutes.  
 After centrifugation, supernatant was discarded and 1ml of medium was added to the 
pellet of cells which have sedimented at the bottom of the tube and was re suspended well in the 
medium with the help of micropipette.  
10µl of this cell suspension was mixed well with 10µl of tryphan blue in an eppendorf 
tube for staining the cells and it was counted in a neubar chamber.  
Procedure for cell counting: 
 After placing the cell suspension along with tryphan blue in haemocytometer, the 
numbers of cells in four corner quadrants were counted.  
 Numbers of cells in left and right top quadrant  = 33 and 39 respectively 
 Numbers of cells in left and right bottom quadrant  = 37 and 33 respectively 
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Total number of cells per ml:  
  33+39+37+33x2x104 
 = 
   4 
 = 71x104 cells/ml 
 71x104 cells were present in 1 ml of cell suspension. 
 Three 96 well plates were taken. Totally 135 wells needs to plate as 45 each of three 96 
well plates. 
Well Design = 8 concentration for ethanolic extract+ 8 concentration for petroleum ether 
extract+8 concentration for ethyl acetate extract+8 concentration for 5-FU+3 for control+10 to 
avoid error. So totally 45 wells are needs to plate. Same procedure continued for remaining  two 
96 well plates to maintain triplicate. 
 we need to plate 135 wells each with 100µl containing 10000cells/well for maintaining 
triplicate condition for control, standard and test extracts.  
 Therefore, 71x104 cells/ml cells were present in 1000µl. 10000cells were present in x µl. 
  
  10000*1000 
 X=  
      71x104 
 = 14.08 µl 
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 14.08µl of cell suspension should be mixed with 85.92µl of medium for plating one well. 
In order to plate 135wells, 1900.8µl of cell suspension was mixed with 11599.2µl of medium to 
get a concentration of 10000cells / 100µl for plating the wells.  
 In order to avoid handling errors cell suspension and medium required for additional 10 
wells were calculated and added along with cell suspension and medium for 135wells.  
 100µl of this cell suspension were seeded into 96 well plate, at a plating density of 10000 
cells/ml and the plate was incubated for 24 hours at 37°c, 5% CO2 for attachment of the cells.  
 After 24hours the seeded cells in the 96 well plate were treated with serial concentration 
of plant extract and the standard drug 5FU.  
 Plant extracts of ethyl acetate, ethanol and Petroleum ether and standard drug were 
initially dissolved in 0.1% v/v DMSO and further diluted in serum free medium to get a desired 
concentration.  
Final volume in each well was 200µl and the plates were incubated again for 48hours.  
Triplicate was maintained for all concentrations and the medium without samples were 
taken as control.  
After 48hours of incubation, medium was removed from the 96 well plate and it was replaced 
with 100µl of phenol red free medium and 15µl of MTT solution was added to the well plates 
and wrapped with aluminium foil as the dye is light sensitive. The plate was incubated again for 
4hours.  
After incubation the medium was carefully removed without disturbing the formed 
formazan crystals and the crystals were solubilised in100µl of 0.1% v/v DMSO and the 
absorbance was measured at 570nm using UV-Spectrophotometer. 
                                 Materials and Methods 
 
Institute of Pharmacology, MMC Page 59 
 
Percentage Cell viability is calculated using the formula  
   Optical density of treated cells 
% Cell Viability  =      x 100 
   Optical density of control cells 
 
    Figure 6.1 Inverted Microscope 
6.3.2 Flourescent microscopic studies: [160] 
 Fluorescent microscopy was used to study the viability of cells as well as nuclei and 
chromatin condensation with the help of fluorescent binding dye.  
 Fully grown or 90% confluency reached two subcultured or passaged flask was taken.  
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 Flask 1 was used for studying the control cancer cells and flask 2 was used for studying 
the extract treated cancer cells.  
 From flask 1 the adhered cells were detached with the help of TPVG solution and the 
TPVG solution containing the cells were centrifuged and the cells were pelleted.  
 The pellet of cells were then resuspended in phosphate buffer saline of pH 7.4. 100 µl of 
this cell suspension was introduced into microscopic slide along with equal mixture of 
acridine orange and ethidium bromide for staining.  
 The cells were then viewed under fluorescent microscope and the viability and nuclear 
changes were studied and photographed.  
 In flask 2, the medium was aspirated and decanted without disturbing the adhered 
monolayer of cells.  
 Flask was then treated with IC50 concentration of effective plant extract such that it 
covers the entire surface area.  
 The flask was then incubated for 48 hours at 5% CO2 and 37°c.  After incubation period, 
the flask was taken and the cells were pelleted and the same procedure was followed as in 
flask 1.  
Extraction of DNA, RNA and Protein using Genei TRI Solution: 
Extraction of DNA, RNA and Protein from the cells which was treated with IC50 
concentration of Ethyl acetate extract, IC50 concentration of 5 Fluorouracil and from cells 
without any treatment were extracted as per Genei TRI Soln Protocol. 
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Fully grown or 90% confluency reached 3 subcultured or passaged flask is taken. The 
medium inside the flask is aspirated and decanted while cells adhered to the monolayer was kept 
intact and the flasks were subjected to drug treatment. 
Flask 1 is replaced with the fresh medium without any test or standard drug and it served as 
Control.  
Flask 2 is treated with IC50 concentration of the effective ethyl acetate extract (IC50 confirmed 
from MTT Assay)  
Flask 3 is treated with IC50 concentration of standard 5 fluorouracil (IC50 confirmed from MTT 
Assay).  
All the three flasks were incubated for 48 hours at 37°c and 5% CO2. After the 
incubation period, the medium inside the flasks were removed and the adhered cells were 
disturbed by treatment with TPVG solution and the TPVG solution containing the suspended 
cells of three flasks were stored in refrigerator for further processing. 
Extraction of RNA :  
Materials Required:  
 Chloroform  
 Isopropyl Alcohol  
 75% Ethanol  
 RNase free water  
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Steps Involved:  
 Homogenisation  
 Phase Separation  
 RNA Precipitation  
 RNA Wash  
 Resuspending RNA  
Procedure:  
Homogenisation:  
Cells were pelleted by centrifugation at 1200rpm for 5minutes.  
The supernatant was decanted and 1ml of TRI solution was added and mixed by 
repetitive pipetting.  
Phase Separation: 
The samples were incubated for 5minutes at room temperature (without exceeding 30°c) 
to completely dissociate nucleoprotein complex.  
0.2ml of chloroform per 1ml of TRI Solution was added, mixed thoroughly and subjected 
to incubation at room temperature (without exceeding 30°c) for 2-3minutes.  
The samples were centrifuged at not more than 12000 rpm for 15minutes at 2-8°c and the 
mixture thus obtained contained a lower phenol chloroform phase, interphase and colourless 
upper aqueous phase. RNA was present in upper aqueous phase.  
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Volume of aqueous phase obtained was about 60% of volume of TRI Solution reagent 
used for homogenization  
RNA Precipitation: 
Aqueous phase was transferred to fresh 1.5ml vial. 0.5ml of isopropanol alcohol per 1 ml 
of TRI Solution was used for initial homogenization. Samples were incubated for 10 minutes at 
room temperature and were subjected to centrifugation at 12000rpm for 10minutes at 2-8°c.  
RNA Wash:  
Supernatant was decanted and the RNA precipitated as gel like pellet on the sides of 
1.5ml vial. RNA pellet was washed once with 75% ethanol, at least 1ml of 75% ethanol was used 
per ml of TRI Solution reagent used for initial homogenization. Solution was centrifuged at 
10000rpm for 10minutes at 2-8°c  
Resuspending RNA:  
RNA pellet was air dried and re-suspended in100µl RNase free water by passing solution 
few times through pipette tip gently. 
Extraction of DNA: 
Materials required:  
 Ethanol (100%)  
 75% Ethanol  
 0.1 M sodium citrate in 10% ethanol.  
 8mM Sodium hydroxide.  
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 Wash Buffer : 0.1 N Sodium citrate in 10% ethanol.  
Steps involved:  
 DNA Precipitation  
 DNA Wash  
 Re suspending the DNA pellet.  
Procedure : 
DNA Precipitation :  
0.3ml of 100% ethanol was added per 1 ml of TRI Solution used for homogenization to 
the inter phase and organic phase which was obtained during phase separation in RNA 
extraction.  
Samples were stored at room temperature without exceeding 30°c for 2-3minutes.  
Samples were centrifuged at 5000rpm for 10minutes at 2-8°c and DNA was obtained as a 
pellet.  
DNA Wash:  
DNA pellet obtained was washed with wash buffer per 1ml TRI Solution used.  
At each wash pellet was stored in wash solution for 30minutes at room temperature 
without exceeding 30°c with periodic mixing. Samples were centrifuged at 5000rpm for 
10minutes at 2-8°c and the wash step was repeated twice.  
Following wash, DNA pellet was suspended in 2ml of 75% ethanol and kept for twenty 
minutes at room temperature and mixed periodically. Samples were centrifuged at 5000rpm for 
10minutes at 2-8°c.  
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Re-suspending the DNA Pellet:  
DNA pellet was air dried for 5-10minutes. DNA pellet was re-suspended in 300µl to 
600µl of 8mM sodium hydroxide so that the concentration of DNA was 0.2 - 0.3µg/ml and 
samples were incubated at room temperature for 15-20minutes.  
Extraction of Protein:  
Materials Required:  
 Isopropyl alcohol  
 Ethanol  
 Wash Buffer: 0.3M Guanidium hydrochloride in 95% ethanol.  
 1% Sodium dodecyl sulphate (SDS)  
Steps involved:  
 Protein precipitation  
 Protein wash  
 Re-suspending Protein pellet  
Procedure:  
Protein precipitation:  
0.3ml of 100% ethanol was added per 1ml of TRI Solution used for homogenization to 
the inter phase and organic phase which was obtained during phase separation in RNA 
extraction.  
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Samples were stored at room temperature without exceeding 30°c for 2-3minutes. 
Samples were centrifuged at 5000rpm for 10minutes at 2-8°c and the supernatant was collected. 
The supernatant was centrifuged at 12000rpm for 10minutes at 2-8°c.  
1.5ml of isopropanol was added to the supernatant per 1.0ml of TRI Solution used for 
initial homogenization and the samples were stored at room temperature without exceeding 30°c.  
Protein Wash:  
The pellet obtained was washed with 2ml of wash buffer per 1 ml of TRI Solution used 
for initial homogenization. The pellets were stored in wash buffer for 20minutes at room 
temperature without exceeding 30°c and were centrifuged at 10000rpm for 5minutes at 2-8°c.  
Wash step was repeated three times and after final wash, protein pellet was vortexed with 
2ml of ethanol and stored in ethanol for twenty minutes. Samples were subjected to 
centrifugation at 10000rpm for 5minutes at 2-8°c.  
Re-suspending Protein Pellet:  
The pellet was vacuum dried for 5-10minutes and was re-suspended in 1% SDS by 
incubating at 50°c for 2-3minutes. Insoluble materials were sedimented by means of 
centrifugation at 10000rpm for 10minutes and the supernatant containing protein were 
transferred into fresh vial.  
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6.3.3 DNA FRAGMENTATION: [161] 
Apoptosis is characterized by cleavage of chromosomal DNA into oligonucleosomal 
fragments. Irregularities in apoptosis have paved way for many diseases like cancer, autoimmune 
disease and neuronal degeneration. This cleavage of DNA or its fragmentation can be visualized 
by DNA laddering assay. 
Cleavage of chromosomal DNA into oligonucleosomal fragments is a hallmark of 
apoptosis. This fragmentation of DNA in cancer cells after treatment with standard drug or test 
extract can be studied with the help of Agarose Gel Electrophoresis. Electrophoresis is a method 
of separating substances based on the rate of movement under the influence of electric field. 
Materials required: 
 Agarose  
 5X TAE buffer  
 6X loading dye  
 DNA ladder  
 Electrophoresis chamber  
 Gel casting tray and comb  
 Ethidium bromide  
 Microwave oven  
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 Power supply 
 Conical flask  
 Sterile tips and pipettes  
Procedure: 
The steps involved are: 
 Preparation of Agarose gel slab  
 Loading of samples  
 Running the gel 
 
    Figure 6.2 Gel Electrophoresis 
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Preparation of Agarose gel slab: 
Gel casting tray and comb was wiped with ethanol and dried. The two open ends of the 
tray were sealed with tape. Place the combs in the gel casting tray. 1.2grams of agarose powder 
was weighed and transferred to 500ml conical flask containing 100ml of TAE buffer.  
Agarose was melted using microwave oven until the solution became clear. The solution 
was cooled to about 50 - 55°c by swirling the flask occasionally or placing it in water bath. 3µl 
of ethidium bromide was added to the solution and mixed well.  
The gel casting tray along with comb was kept horizontally on a flat even surface.  
Agarose solution was poured evenly on the casting tray such that it covers the entire 
surface evenly without any bubble formation and was allowed to cool and solidify into a gel slab. 
After solidification, remove the tapes from both ends of the tray and place the gel in 
electrophoresis chamber and add enough TAE buffer so that there is 2-3mm of buffer over the 
gel and carefully pull out the comb out of the tray to form wells.  
Loading of samples:  
DNA which was extracted from the control, standard and extract treated cancer cells were 
quantified by means of nano drop method. Based on the quantification, equal quantity of DNA 
was taken and mixed with required TAE buffer to make a final volume of 10µl each for a 
sample.  2µl of 6X loading dye was added to the DNA sample and mixed well.  10µl of 100 base 
pair standard DNA ladder and 12µl of DNA samples were loaded carefully in the submerged 
wells of gel slab in the electrophoresis chamber.  
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Running the Gel:  
Lid was placed on the gel box and the electrodes were connected. Electrode wires were 
connected to power supply and power supply of about 80 volts were applied. Power supply to the 
electrophoresis chamber was ensured until the blue dye approached the end of the gel.  Later 
power supply was cut off, wires were disconnected and the lid was removed.  Gel tray was 
carefully taken out and the gel was placed inside the Gel photostation and photographed in 
presence of UV light.  
6.3.4 PROTEIN ASSAY: 
Instrument: Agilent high sensitivity protein 250 bio analyzer 
Agilent high sensitivity protein 250 bio analyzer was used to identify and quantify the 
proteins present in cancer cells, without any treatment and in cancer cells after treatment with 
standard drug and test extract. Proteins isolated from control and treated cancer cells were 
quantified by nano drop spectrophotometer and equal quantity of protein was subjected to series 
of processing as described below and was identified and quantified with the help of standard 
ladder using bio analyzer. The procedure was carried out as per Agilent high sensitivity protein 
250 bio analyzer protocol. 
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    Figure 6.3 Agilent Bio analyzer 
Materials required: 
 Isolated proteins from control and treated cancer cells  
 10X protein 250 standard labeling buffer  
 Ethanolamine  
 DMSO  
 Labeling dye  
 Ladder  
 Gel matrix 
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 Destaining solution  
 Sample buffer  
 Dithiothreitol  
 High sensitivity protein chip  
 Micropipette and tips.  
 
  Figure 6.4 Agilent Bio analyzer with complete set up. 
Steps involved: 
Covalent labeling of proteins with fluorescent dye : 
 Preparation of dye  
 Preparation of denaturing solution  
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 Processing of protein  
 Labeling of protein/ladder  
 Protein and ladder preparation  
Separation and detection of labeled proteins with on chip electrophoresis: 
 Loading the gel matrix  
 Loading the sample  
 Inserting a chip in bio analyzer  
 Starting the chip run  
Procedure: 
A. Covalent labeling of proteins with fluorescent dye.  
Preparation of dye:  
 Fluorescent dye and DMSO was thawed to room temperature.  
 After thawing, 50µl of DMSO was added to the dye vial provided in the kit and mixed 
well.  
 Dye solution was stored at - 20°c in amber coloured vial to avoid degradation on light 
exposure.  
Preparation of denaturing solution:  
 Denaturing solution was prepared by adding 100µl of sample buffer to 3.5µl of 1M 
dithiothreitol.  
Processing of protein:  
 pH of the protein samples were adjusted to 8.0 – 9.0 by adding 10X standard labeling 
buffer in the ratio 1:9.  
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Labeling of protein/ladder:  
 0.5µl of prepared dye was added to 5µl of ladder/protein sample and incubated for 
30minutes on ice to facilitate uniform labeling.  
 After incubation 0.5µl of ethanolamine was added to remove/quench the excess dye and 
incubated for 10minutes on ice.  
 Later, labeled reaction mix was diluted to 200 times (1:200) with water.  
Protein and ladder preparation:  
 2µl of denaturing solution was added to 4µl of labeled, diluted protein/ladder and mixed 
well.  
 The reaction mix was heated in a heating block or boiling water bath at 95 to 100°c for 5 
minutes.  
 Later the samples were cooled to room temperature and spinned for 15seconds and used 
for analysis of proteins.  
B. Separation and detection of labeled proteins with on chip electrophoresis:  
Loading the Gel matrix:  
 Gel matrix was allowed to equilibrate to room temperature for 30minutes before use.  
 High sensitivity protein chip was taken out of sealed bag and placed on chip priming 
station.  
 12µl of gel was pipetted into the bottom of the well marked G as shown in Figure 6.5. 
 Plunger was positioned at 1ml and the chip priming station was closed, setting the timer 
to 90 seconds as shown in figure6.5.  
 Plunger of the syringe was pressed down until it was held by the clip and pressure was 
applied as shown in figure6.5. 
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 After 90 seconds plunger was released with the clip release mechanism and its movement 
back to 0.3 ml was inspected visually.  
 After 5 seconds plunger was pulled back to 1ml position and the chip priming station was 
opened.  
 12µl of gel mix was pipetted into each of three wells marked with G as shown in 
figure6.5.  
 12µl of destaining solution was pipetted into the well marked DS as shown in figure6.5. 
 
 
Loading the samples:  
 Heat denatured isolated protein samples of control cancer cells and standard and test 
extract treated cancer cells of volume 6µl was pipetted into the sample wells marked 1 to 
3 and the remaining wells were filled with equal volume of water as shown in figure6.5.  
Figure 6.5 High sensitivity Protein Chip 
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 Heat denatured ladder of volume 6µl was pipetted into the well marked with ladder 
symbol L as shown in figure6.5.  
Inserting a chip in bio analyzer:  
 Lid of the bio analyzer was opened and the electrode cartridge was inserted into the 
instrument.  
 Chips were placed carefully into the receptacle and the lid was closed carefully ensuring 
the electrodes in the cartilage fit into the wells of the chip.  
 Insertion of the chip was confirmed by appearance of chip icon at the top left of the 
instrument context in the 2100 expert software screen. 
Starting the chip run:  
 High sensitivity protein 250 assay was selected from the assay menu in the instrument 
context.  
 File storage location and the number of samples to be analysed was selected.  
 Chip run was started by clicking START button in the upper right of the window of 2100 
expert software screen.  
 After the samples were analysed, the data’s were stored in the instrument context and the 
protein of our interest was studied from the data obtained.  
6.3.5 Real time Reverse Transcriptase Polymerase Chain Reaction: [162] 
Real time reverse transcriptase polymerase chain reaction is abbreviated as qRT-PCR. It 
is a technique where expression of RNA is studied by converting it into cDNA with the help of 
enzyme reverse transcriptase and quantitatively measuring the amount of amplified target 
                                 Materials and Methods 
 
Institute of Pharmacology, MMC Page 77 
 
sequence from entire cDNA using fluorescent dye SYBR green in real time.Upon binding with 
DNA, SYBR green dye used will emit fluorescence and the fluorescence intensity is directly 
proportional to number of DNA copies or expression produced. The fluorescence which is 
emitted is analysed by detector with the help of LED source and it gives the relative expression 
of genes. The procedure was carried out as per Step 1 plus ABI protocol. 
Procedure: 
Complementary DNA Synthesis:  
Materials Required:  
 5X buffer  
 10mm dNTPs  
 Hexamer primer  
 Extracted RNA  
 Thermal cycler  
 Reverse transcriptase  
 DTT  
Procedure:  
 In 200µl eppendorf tubes, 5µl of 5X buffer, 2µl of 10mm DNTPs and 1.5µl of hexamer 
primer was added.  
 Later 15µl of extracted RNA was added and the eppendorf tubes were kept in thermal 
cycler at 70°c for 5 minutes to separate the false double stranded RNA.  
 The tubes were taken out and immediately cooled with ice to prevent binding of false 
double stranded RNA again.  
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 1.5µl of Reverse transcriptase and 1µl of DTT was added to the tube and spun for few 
seconds.  
 It was then placed in thermal cycler , 25°c for 5minutes, for binding of hexamer, followed 
by 42°c for 45minutes for cDNA synthesis, followed by 85°c for 5minutes for 
denaturation of remaining unconverted RNA’s and finally at 4°c for 5minutes.  
Primer synthesis: 
The primers synthesized were P53, Bcl2, TNF α and IL – 6 along with house keeping 
gene GPDH. The primers were synthesized by Geno Rime with the help of Primer express 
software with the available primer sequence. 
PRIMER NAME PRIMER SEQUENCE FROM 5’ - 3’ 
 
P53 
 
AGGGATACTATTCAGCCCGAGGTG 
ACTGCCACTCCTTGCCCCATTC 
 
Bcl-2 
 
ATGTGTGTGGAGAGCGTCAACC 
TGAGCAGAGTCTTCAGAGACAGCC 
 
TNFα 
 
TCTCTAATCAGCCCTCTGGCC 
TGGGCTACAGGCTTGTCACTC 
 
IL-6 
 
GCCTTCGGTCCAGTTGCCTT 
GCAGAATGAGATGAGTTGTC 
 
GPDH 
 
ATTGACCACTACCTGGGCAA 
GAGATACACTTCAACACTTTGACCT 
 
                                 Materials and Methods 
 
Institute of Pharmacology, MMC Page 79 
 
The concentration of primers synthesized were 100pM/µl. It was diluted in the ratio of 1: 
10 with water to get a concentration of 10pM/µl. 
Real time PCR: 
 The materials required are  
 25µl of SYBR green RT mix 5µl of cDNA 2µl of 25 pM/µl forward primer 2µl of 25 
pM/µl reverse primer 16µl PCR grade water.  
 For a total of 50 µl reaction, the above mentioned mixtures were added into eppendorf 
tubes and they were placed in real time PCR instrument and the program was set as 
follows:  
Step 1: Pre denaturation at 95˚C for 1minute  
Step 2: Denaturation at 95˚C for 15seconds  
Step 3: Annealing at 60˚C for 15seconds  
Step 4: Extension at 72˚C for 45seconds Step 2 to step 4 repeated for 40 cycles.  
 The relative expression of genes was analyzed and interpreted and by Applied Biosystem 
Software.  
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7. RESULTS 
7.1 Phytochemical Analysis: 
Phytochemical analysis was carried out for petroleum ether, ethyl acetate and ethanol 
extracts of Evolvulus alsinoides and the results are shown in table. 
CONSTITUENTS Petroleum ether 
Extract 
Ethanol Extract Ethyl acetate 
Extract 
Alkaloids Absent Present Absent 
Steroids Present Present Present 
Flavanoids Absent Present Present 
Tannins/Phenol Absent Present Absent 
Proteins Absent Present Absent 
Carbohydrate Absent Present Absent 
Glycosides Present Present Present 
Terpinoids Absent Absent Present 
Table 7.1 Phytochemical analysis of the various extracts of Evolvulus alsinoides 
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CYTOTOXICITY TEST: 
7.2 MTT Assay: 
 MTT assay was carried out with Petrolium ether, ethyl acetate and ethanol extract of 
Evolvulus alsinoides and with 5-Fluorouracil and the results are shown. 
MTT Assay of Ethanolic Extract of Evolvulus alsinoides 
S.No Concentration 
(µg/ml) 
Dilutions Absorbance Cell viability (%) 
(O.D) 
1 1000 Neat 0.09 16.66 
2 500 1:01 0.15 27.77 
3 250 1:02 0.19 35.18 
4 125 1:04 0.23 42.59 
5 62.5 1:08 0.27 50 
6 31.2 1:16 0.32 59.25 
7 15.6 1:32 0.39 72.22 
8 7.8 1 64 0.45 83.33 
9 Cell control - 0.54 100 
Table7.2 IC50 concentration and %cell viability of ethanolic extract of Evolvulus alsinoides 
Figure:7.1  Graphical representation of  % cell viability vs Concentration in µg/ml  of 
ethanolic extract of Evolvulus alsinoides 
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MTT Assay of Petroleum ether Extract of Evolvulus alsinoides 
S.No Concentration 
(µg/ml) 
Dilutions Absorbance Cell viability (%) 
(O.D) 
1 1000 Neat 0.15 27.77 
2 500 1:01 0.19 35.18 
3 250 1:02 0.26 48.14 
4 125 1:04 0.29 53.70 
5 62.5 1:08 0.32 59.25 
6 31.2 1:16 0.36 66.66 
7 15.6 1:32 0.39 72.22 
8 7.8 1 64 0.45 83.33 
9 Cell control - 0.54 100 
 
Table7.3 IC50 concentration and % cell viability of Petroleum ether extract of Evolvulus 
alsinoides. 
 
 
Figure7.2 Graphical representation of  % cell viability vs Concentration in µg/ml  of 
Petroleum ether extract of Evolvulus alsinoides. 
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MTT Assay of Ethyl acetate Extract of Evolvulus alsinoides 
S.No Concentration 
(µg/ml) 
Dilutions Absorbance Cell viability (%) 
(O.D) 
1 1000 Neat 0.03 5.55 
2 500 1:01 0.08 14.81 
3 250 1:02 0.1 18.51 
4 125 1:04 0.14 25.92 
5 62.5 1:08 0.18 33.33 
6 31.2 1:16 0.23 42.59 
7 15.6 1:32 0.28 51.85 
8 7.8 1 64 0.38 70.37 
9 Cell control - 0.54 100 
 
Table7.4  IC50 concentration and % cell viability of Ethyl acetate extract of Evolvulus 
alsinoides. 
 
 
Figure7.3 Graphical representation of  % cell viability vs Concentration in µg/ml  of Ethyl 
acetate extract of Evolvulus alsinoides. 
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MTT Assay of 5-Fluorouracil 
S.No Concentration 
(µg/ml) 
Dilutions Absorbance Cell viability 
(%) 
(O.D) 
1 1000 Neat 0.01 1.85 
2 500 1:01 0.03 5.55 
3 250 1:02 0.06 11.11 
4 125 1:04 0.1 18.51 
5 62.5 1:08 0.13 24.07 
6 31.2 1:16 0.17 31.48 
7 15.6 1:32 0.2 37.03 
8 7.8 1 64 0.28 51.85 
9 Cell control - 0.54 100 
 
Table7.5 IC50 concentration and % cell viability of 5-Fluorouracil 
 
 
Figure7.4 Graphical representation of % cell viability vs Concentration in µg/ml of 5 
Fluorouracil 
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(A)                                                                                   (B) 
   
(C)                                                                                  (D) 
   
(E)                                                                                  (F) 
   
(G)                                                                                  (H) 
Figure 7.5 A549 cells treated with Ethyl acetate extracts – (A) Control, (B)7.8 µg/ml, 
(C)15.6 µg/ml, (D)31.2 µg/ml, (E)62.5 µg/ml , (F)125 µg/ml, (G) 250 µg/ml, (H)1000 µg/ml. 
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7.3 APOPTOSIS: 
Flourescence microscopic observation: 
Control cells without any drug or extract treated were bright green in colour.  
Cells treated with ethyl acetate extract of Evolvulus alsinoides  were bright orange in 
colour with loss of membrane integrity and cytoplasmic contents leaking out of the cell.  
The observations of light microscopic studies and fluorescent microscopic studies are 
depicted in figures 
 
Figure 7.6 A549 cells – Control, indicting viable cells stained green in colour  
 
 
Figure 7.7 A549 cells after treatment with Ethyl acetate extract of Evolvulus alsinoides 
showing dead cells stained orange in colour with loss of membrane integrity and 
cytoplasmic contents leaking out of the cell. 
 
                                 Results 
 
Institute of Pharmacology, MMC Page 87 
 
7.4 DNA FRAGMENTATION: 
 In the control A549 cells, there was no fragmentation observed in agarose gel. 
Fragmentation was observed in A549 cell treated with IC50 concentration of standard 5-
Fluorouacil and ethyl acetate extract of Evolvulus alsinoides. This Fragmentation of DNA in 
ethyl acetate extract treated cells indicated the characteristics of apoptotic cells. 
Results obtained in fragmentation studies are shown in figure. 
 
Figure 7.8 . DNA Fragmentation in A549 cells. 
Lane 1: 100 base pair DNA marker  
Lane 2: A549 cells treated with 5-Fluorouracil  
Lane 3: A549 cells treated with ethyl acetate extract of Evolvulus alsinoides 
Lane 4: A549 cells without any treatment. 
LANE-1 
LANE-2 
LANE-3 
LANE-4 
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7.5 PROTEIN ASSAY: 
 Quantification of proteins, C reactive protein and Phospho histidine phosphatase present 
in A549 cells treated with IC50 concentration of ethyl acetate extract of Evolvulus alsinoides and 
5-fluorouracil and also from cells without any treatment were analysed using Bio analyzer. 
The results obtained were given in Table and in Figures. 
 
Figure7.9 . Gel Image of Protein analysis 
5 
15 
28 
46 
63 
95 
150 
240 
Ladder A549 Control A549 5-FU A549-Evolvulus 
alsinoides 
14KDa 
21KDa 
KDa 
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Quantification Of Protein: 
C-Reactive Protein: 
 
Protein Treatment Size(KDa) Concentration(pg/ml) 
 
 
 
C-Reactive 
Protein 
A549- Control 20.2 420.5 
A549-5-Flourouracil 21.4 330.7 
A549 Ethyl acetate extract of 
Evolvulus alsinoides 
20.8 354.6 
Table7.6  Quantification of Protein- C-Reactive protein 
 
 
Figure7.10  Graphical representation of concentration of C Reactive Protein in A549 cells 
before treatment and after treatment with ethyl acetate extract of Evolvulus alsinoides and 
5 fluorouracil. 
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Phospho histidine phosphatase: 
 
Protein Treatment Size(KDa) Concentration(pg/ml) 
 
 
Phospho 
histidine 
phosphatase 
A549- Control 14.0 128.0 
A549-5-Flourouracil 13.9 65.2 
A549 Ethyl acetate extract of 
Evolvulus alsinoides 
13.8 86.4 
 
Table 7.7: Quantification of Protein- Phospho histidine phosphatase 
 
 
Figure7.11. Graphical representation of concentration of Phospho histidine phosphatase in 
A549 cells before treatment and after treatment with ethyl acetate extract of Evolvulus 
alsinoides and 5 fluorouracil. 
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7.6 Gene  Expression Studies: 
P53 Gene in A549 Cell Line : 
 
                                    
    Figure 7.12 p53 Expression 
M:Marker- 1 kb DNA Ladder 
1: Standard- 5-Flourouracil 
2: Test- IC50 concentration of Ethyl acetate extract of Evolvulus alsinoides 
3: Control- Without any treatment 
 
 
 
 
M       1            2    3 
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Expression levels of P-53: 
 
Table7.8: Expression levels of P-53 
 
Graphical representation of p53 expression 
 
Figure7.13: Graphical representation of p53 expression 
 
 
 
P-53 Relative Quantitation Standard Error 
Standard- 5 Fluorouracil 5.23 0.1 
Ethyl acetate Extract 4.62 0.12 
Control 1.41 0.03 
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Bcl2 Gene in A549 Cell Line : 
 
 
 
Figure 7.14 Bcl2 Expression 
M: Marker DNA 
1: Control - Without any treatment 
2: Standard- 5-Fluorouracil 
3:Test-  IC50 concentration of Ethyl acetate extract of Evolvulus alsinoides 
 
M  1              2            3 
300 Bp 
                                 Results 
 
Institute of Pharmacology, MMC Page 94 
 
Expression levels of Bcl2: 
 
Table7.8: Expression levels of Bcl2 
 
Graphical representation of Bcl2 expression: 
 
Figure7.15: Graphical representation of Bcl2 expression. 
 
 
 
Bcl2 Relative Quantitation Standard Error 
Control 6.17 0.12 
5-Fluorouracil 3.62 0.106 
Ethyl acetate Extract 3.81 0.09 
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TNF-α  Gene in A549 Cell Line : 
 
 
 
    Figure 7.16: TNF alpha Expression 
M: Marker DNA 
1: Control - Without any treatment 
2: Standard- 5-Fluorouracil 
3:Test-  IC50 concentration of Ethyl acetate extract of Evolvulus alsinoides 
 
 
 
      M            1      2          3 
296 Bp 
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Expression levels of TNF-α: 
 
Table7.9: Expression levels of TNF-α 
Graphical representation of TNF-α expression: 
 
Figure7.17: Graphical representation of TNF-α expression 
 
 
 
 
P-53 Relative Quantitation Standard Error 
Control 1.21 0.11 
5-Fluorouracil 4.12 0.041 
Ethyl acetate Extract 3.42 0.03 
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IL-6  Gene in A549 Cell Line : 
 
 
 
    Figure 7.18: IL-6 Expression 
M: Marker DNA 
1: Standard- 5-Fluorouracil 
2: Control - Without any treatment 
3:Test-  IC50 concentration of Ethyl acetate extract of Evolvulus alsinoides 
 
1  2        3  M 
348 Bp 
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Expression levels of IL-6: 
 
Table7.10: Expression levels of IL-6 
Graphical representation of IL-6 expression: 
 
Figure7.19: Graphical representation of IL-6 expression 
 
 
 
 
P-53 Relative Quantitation Standard Error 
Control 8.62 0.01 
5-Fluorouracil 6.42 0.06 
Ethyl acetate Extract 6.12 0.03 
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8. DISCUSSION 
 Cancer is considered as a serious health problem worldwide. Lung cancer remains a 
major global health problem and leading cause of cancer mortalities in most of the countries in 
the world with approximately 1.3 million new cases and 300000 deaths each year estimated by 
World Health Organisation. Lung cancer has been classified into two groups namely small cell 
and non small cell lung cancer, with the latter being more prevalent accounting for nearly 80% of 
lung cancer cases. 
With increase in mortality rates among patients suffering from cancer and with limited 
success being achieved in clinical therapies including radiation, chemotherapy, immune 
modulation and surgery in treating cancer patients, there arises a need for new way of cancer 
management. 
Natural phytochemicals derived from medicinal plants have attained a greater 
significance in potential management of several diseases including cancer. Several researches 
have been carried out in evaluation of plant extracts as prophylactic agents which offer greater 
potential to inhibit carcinogenic process. 
The mechanism of inhibition of tumour progression by natural phytochemicals range 
from inhibition of genotoxic effects, increased anti inflammatory and anti oxidant effect, 
inhibition of cell proliferation, protection of intracellular communications to modulate apoptosis 
and signal transduction pathways. 
Discovery of effective herbs and elucidation of their underlying mechanisms could lead 
to development of an alternative and complimentary method for cancer prevention and treatment.  
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Medicinal plants constitute a common alternative for cancer prevention and treatment in 
many countries around world. Currently more than 3000 plants around world have been reported 
to possess anti cancer properties. 
Screening of different plant components in search of anti cancer drugs is one of the main 
research activities throughout the world. Vinca alkaloids and cytotoxic podophyllotoxins were 
discovered in the 1950’s as first anticancer agents from plants. In addition to several plants 
extracted compounds such as camptothecin, vincristine, vinblastine, taxol and podophyllotoxin , 
many of the natural compounds were structurally modified to result in stronger anti cancer 
analogues with less adverse effects. 
 Evolvulus alsinoides plant used traditionally to treat bowel problems and to promote 
conception. The entire plant was considered astringent and useful for treating haemorrhages, and 
there are a variety of other medical applications, including use as an adaptogenic, antiphlogistic, 
antipyretic, antiseptic, aphrodisiac, febrifuge, stomachic, tonic, and vermifuge, in the treatment 
of asthma, bronchitis, scrofula, syphilis, or in “controlling night emissions” and to promote 
wound healing.  
Phytochemical analysis has revealed the presence of alkaloids, tannins, steroids and 
flavanoids. It has been reported with adaptogenic, anxiolytic, anti-amnesic, antioxidant, 
antiulcer, anticatatonic, anti Diarrhoeal, anti-inflammatory, antipyretic and immunomodulatory 
activity.There was no previous study to prove its anti cancer activity. So the study was carried 
out to evaluate the anticancer effect of extracts of leaves of Evolvulus alsinoides and the gene 
expression levels playing a role in cancer pathology using in vitro models. 
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Dried whole plant of Evolvulus alsinoides were extracted with solvents like petroleum 
ether, Ethyl acetate and Ethanol. Cytotoxic activity was carried out in lung cancerous cell line 
A549 with extracts of ethyl acetate, ethanol and was compared with standard drug 5 
Fluorouracil. Test for cytotoxicity was carried out by MTT assay and among the three extracts 
evaluated, the effective extract was found to be ethyl acetate extract with a IC50 value of 
15.6µg/ml followed by ethanol and petroleum ether extract with IC50 value of  62.5 µg/ml and 
250 µg/ml respectively. IC50 value of 5 Fluorouracil was found to be 7.8 µg/ml. Linearity was 
expressed with the help of graph plotted in Microsoft excel. 
Ethyl acetate extract was found to be more effective of all three extracts by carrying out 
MTT assay and further studies were carried out with extract of ethyl acetate. Apoptotic study 
was carried out by Microscopic analysis and DNA fragmentation. 
Apoptotic effect of IC50 concentration of ethyl acetate extract of Evolvulus alsinoides 
treated A549 cells were further confirmed with the help of fluorescence microscopy using 
acridine orange and ethidium bromide. Acridine orange is a vital dye capable of staining both 
dead and live cells, where as ethidium bromide will stain only cells that have lost their 
membrane integrity. On examination of cells without any treatment under fluorescent 
microscope, the cells were stained green in colour representing viable or live cells, whereas 
examination of cells after treatment with ethyl acetate extract showed reddish or orange colour 
with loss of membrane integrity and leakage of cytoplasmic contents representing dead cells and 
and the obtained results were similar to those reported by Shahrul Hisham Zainal Ariffin et al in 
Hep G2 cells. This led to confirmation that ethyl acetate extract of Evolvulus alsinoides showed 
apoptotic effect in lung cancerous cell line A549. 
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DNA fragmentation study was carried out by extracting DNA from the cells after 
treatment with IC50 concentration of ethyl acetate extract of Evolvulus alsinoides and standard 5 
Fluorouracil for 48 hours and also from cells without any treatment. Apoptosis is characterized 
by cleavage of chromosomal DNA into oligonucleosomal fragments. Cleavage of chromosomal 
DNA into oligonucleosomal fragments is a hallmark of apoptosis and apoptotic cells often 
produce nucleotide fragments at an interval of 180-200 base pairs, visualized by DNA agarose 
gel electrophoresis. On examination, DNA fragmentation appeared in A549 cells treated with 
ethyl acetate extract and 5 fluorouracil when compared to cells without any treatment, which did 
not show any fragmentation. The results obtained were similar to the results shown by 
Abhimanyu kumar Jha et al  using SiHa cell line. This fragmentation of DNA indicated the 
characteristics of apoptotic cells. Thus ethyl acetate extract of Evolvulus alsinoides causes DNA 
damage in A549 cells, thereby inducing apoptosis. 
Protein levels in cancer cells before and after treatment with extract and 5 Flourouracil 
were studied using bio analyzer. C Reactive Protein is a 21KDa protein, a systemic biomarker of 
inflammation whose levels were found to be high in malignancies indicating a close linkage 
between inflammation and malignancy. It was reported that C reactive protein levels were high 
in patients suffering from lung cancer and there was a strong association of elevated levels of 
CRP with tobacco related lung cancer. CRP lowering agents may have promising role in 
prevention and therapy of malignancies in future. Another protein associated with lung cancer is 
14KDa phosphohistidine phosphatase which was reported to play a role in lung cancer cell 
migration and invasion. 
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The levels of these two proteins were quantified in A549 cells after treatment with ethyl 
acetate extract of Evolvulus alsinoides and standard for 48 hours. C reactive protein present in 
A549 cells without any treatment were found to be 420.5 pg/µl, whereas in cells treated with 
ethyl acetate extract and standard were found to be 354.6 pg/µl and 330.7 pg/µl respectively. 
Similarly Phospho histidine phosphatase present in A549 cells without any treatment were found 
to be 128 pg/µl, whereas in cells treated with ethyl acetate extract and standard were found to be 
86.4 pg/µl and 65.2 pg/µl. This marked reduction in protein levels which are said to be associated 
with lung cancer risk in cells after treatment shows that the ethyl acetate extract of Evolvulus 
alsinoides posses the anti cancer effect. 
Cancer DNA markers like p53, Bcl2, TNF-α and immune response marker IL-6 plays a 
major role in cancer pathology and their expression levels determine the progression of the 
disease. These gene expression levels were studied in cells treated with IC50 concentration of 
ethyl acetate extract of Evolvulus alsinoides and 5-Fluorouracil by RT-PCR methodology using 
SYBR green. 
The expression levels of p53 was found to be increased in cells treated with ethyl acetate 
extract of Evolvulus alsinoides and in cells treated with 5-Fluorouracil when compared to cells 
without any treatment, indicating the ability of ethyl acetate extract to up regulate p53 and 
promote apoptosis. The expression levels of TNF-α was found to be increased in cells treated 
with ethyl acetate extract and in cells treated with 5 Fluorouracil when compared to cells without 
any treatment, indicating the ability of ethyl acetate extract to induce apoptosis by increasing the 
expression of TNF-α. The results obtained agreed with those obtained by Azizi et al and Ali 
Alshehri. 
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High expression of anti-apoptotic members like Bcl-2 found in human cancers leads to 
neoplastic cell expansion by interfering with normal cell death mechanism. Decrease in 
expression of Bcl-2 leads to apoptosis. The expression levels of Bcl-2 in ethyl acetate extract 
treated cells and 5 Fluorouracil treated cells was found to be decreased when compared to 
expression in cells without any treatment which implies that apoptosis in A549 lung cancerous 
cells may be due to decreased expression of Bcl-2. The results obtained were similar to those 
reported by Gul Ozcan Arican et al in Hela cells. 
Immune response marker IL-6 plays a role in cancer. High serum IL-6 levels were 
detected in patients with lung, breast, prostate, colorectal, gastric, pancreatic, ovarian and renal 
cell cancers. High serum IL-6 levels were associated with progressive diseases and poor survival. 
Expression of IL-6 in control cells were found to be high when compared to cells treated with 
ethyl acetate extract and cells treated with standard 5 Fluorouracil indicating that apoptosis in 
cells of A549 may be due to decreased expression of IL-6. These gene expression levels 
indicates that ethyl acetate extract of Evolvulus alsinoides exhibits apoptotic effect by over 
expression of p53, TNF-α and down regulation of Bcl-2 and immune response marker IL-6. 
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9. CONCLUSION 
 Evaluation of Phytochemical analysis of ethyl acetate, ethanol and petroleum ether extracts 
of Evolvulus alsinoides revealed the presence of proteins, alkaloids, tannins, steroids, phenols 
and flavanoids.  
 In this present study, Ethyl acetate extract of Evolvulus alsinoides was found to possess 
potent cytotoxic activity in human lung cancerous cell line A549 and was compared with 
standard drug 5 Fluorouracil.  
 The Apoptotic effect was confirmed in treated cells by appearance of loss of membrane 
integrity, leakage of cytoplasmic contents and fragmentation of DNA in treated cells.  
 Its anti cancer effect was further confirmed by reduced levels of proteins Phospho histidine 
phosphatase and C Reactive Protein in ethyl acetate extract of Evolvulus alsinoides  treated 
cells, whose elevated levels are said to possess a risk in cancer development.  
 Its apoptotic and anti cancer effect may be due to up regulation of genes like p53 and TNF α 
and down regulation of genes like Bcl-2 and IL-6, which was confirmed by RT-PCR.  
 These results show that ethyl acetate extract of Evolvulus alsinoides possess anti cancer 
effect and for future perspective, it can be further confirmed by isolating the compounds 
responsible for the activity and studying the exact mechanism by which the plant possess this 
activity and confirm the results using in vivo animal models.  
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